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Two-dimensional echocardiography is a commonly used non-invasive method for the assess-
ment of left ventricular function. It provides precise information on both global and segmental
myocardial function by displaying endocardial motion and wall thickening.
Dobutamine stress echocardiography (DSE) is currently the leading non-invasive imaging
technique for the diagnosis and prognosis of coronary artery disease (CAD), the documentation
of myocardial viability and for long-term risk stratification [1]. The term clinical stress echocar-
diography is starting to be applied as DSE is used in different clinical settings.
Outline of the Thesis
Part 1: Improving Accuracy
Dobutamine stress echocardiography is widely used for the diagnosis of coronary artery dis-
ease and the detection of myocardial viability. However assessment of endocardial motion and
wall thickening from two-dimensional echocardiography images largely depends on image qual-
ity and is both subjective, and qualitative [2]. This may result in interobserver variability. More-
over the sensitivity of DSE for detecting CAD ranges from 81% to 85% with a similar specificity
range. These values are less in the presence of single vessel disease [2]. Nevertheless they are
similar to single-proton emission tomography (SPECT) and the other non-invasive stress imag-
ing modalities for both  the detection of myocardial ischemia and viability [2-7].
Therefore effort should focus either on the development of more sophisticated quantitative
techniques or on the improvement of the existing methodology. These should take into account
several criteria and should aim at an increase in sensitivity without loss in specificity [8].
Chapter 1 of this thesis is an experimental paper. As part of a muticenter study DSE data from
several centres were used to design a coupled-contour and robust fusion technique for an objec-
tive assessment of myocardial wall motion abnormalities.
Cardiac ultrasound is a reflection technique. In addition to the fast motion of the heart, respi-
ratory interferences pose additional problems in the analysis [9]. The above mentioned technique
takes into account several parameters such as the shape and the motion of both the endocardium
and epicardium, providing important information on both excursion and myocardial thickening
[8] [9] [10]. Preliminary data have shown maintained sensitivity and increased specificity for the
detection of CAD and reduced inter- and intra-observer variability of DSE. It is the first robust
automatic coupled-contour myocardial tracking technique that utilizes the thickening of the myo-
cardium during systole.
In Chapter 2 we estimated, in 200 patients, the additional diagnostic value of new or worsen-
ing wall motion abnormalities (NWMA) during the recovery phase of DSE after receiving acute
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beta-blockade compared to findings at peak and using coronary angiography as reference.
One limitation of DSE is the modest sensitivity in patients with single vessel CAD. The assess-
ment of wall motion abnormalities during the recovery phase after acute beta blockade improves
the sensitivity of DSE particularly in patients with single vessel CAD. Sensitivity in this subgroup
increased significantly from 81% to 99% (p<0.001) while specificity was marginally decreased.
There was also a prolonged  ischemic effect of dobutamine during the recovery phase. So obser-
vation and scoring of individual segments at recovery phase, as part of the regular DSE scoring,
in patients that receive acute beta-blockade at peak stress, could add to the better assessment of
ischemia in CAD patients.
Chapter 3 further evaluates the recovery phase of DSE after acute beta-blocker administra-
tion at peak stress, in the setting of myocardial viability estimation and using dual-isotope single
photon emission tomography (DISA-SPECT) as reference. We studied 49 consecutive patients
with ejection fraction (LVEF) ≤35%. Patients with ≥4 viable segments were considered viable
and radionuclide LVEF was performed prior and twelve months after revascularization. It is
known that myocardial viability assessment in severely dysfunctional segments by dobutamine
echocardiography (DSE) is less sensitive than nuclear scanning. However we demonstrate that
the recovery phase of DSE has an increased sensitivity for viability estimation compared to low-
high dose DSE. The sensitivity at low-high DSE for viability estimation was 72% (95% CI 68%
to 76%) and specificity 74% (95% CI 72% to 76%). When recovery images were also analyzed
the sensitivity for viability estimation increased to 85% (95% CI 81% to 89%), while specificity
remained unchanged. Moreover multivariate regression analysis showed that, DSE with recov-
ery phase was the only independent predictor of ≥ 5% LVEF improvement after revasculariza-
tion. Therefore the assessment of myocardial viability by DSE in patients with coronary artery
disease has improved sensitivity when scoring of individual segments at recovery phase becomes
an integral part of the regular DSE scoring.
Part 2: Prediction of Outcome and Risk Stratification
The safety, accuracy and feasibility of DSE have well been established [1]. Several studies
have demonstrated the high predictive value of DSE for long-term cardiac events in a large group
of patients [11-13]. However the role of the recovery phase of DSE is underestimated and its
value in long term prognosis of patients is yet to be determined.
Moreover the risk stratification in patients undergoing vascular surgery according to their
myocardial viability status or the role of DSE according to the entire strata of renal function needs
to be clarified.
In Chapter 4 we assess the prognostic value of wall motion abnormalities (WMA) during
recovery phase of dobutamine stress echocardiography (DSE) in addition to WMA at peak
stress, in 187 consecutive patients for a mean follow up of 36 (± 28) months. Observation and
scoring of individual segments at recovery phase, as part of the regular DSE scoring, improve the
assessment of myocardial ischemia in CAD patients. The presence of myocardial ischemia
(NWMA) during recovery phase was the only independent DSE predictor of late cardiac events
and has an incremental value when added to ischemia at peak. Patients that exhibited ischem-
ic response only in the recovery phase and after acute beta-blockade had a delayed event than
those that presented ischemia at peak.
In Chapter 5 we developed, a quantitative prognostic model for HF patients scheduled for
surgery using wall motion patterns during dobutamine stress echocardiography (DSE) in 295
consecutive patients with ejection fraction <35%. Cardiac death and myocardial infarction were
noted perioperatively and during 5 year follow-up. We demonstrated that DSE provides an
accurate risk stratification of HF patients undergoing vascular surgery. Therefore by utilizing
DSE we further stratified those patients with resting LV dysfunction, according to their viability
profile. Sustained improvement during DSE provided a protective effect in both early perioper-
ative period and long-term cardiac events. On the contrary ischemia proved to be hazardous in
both early and long-term follow up periods.
In Chapter 6 we assessed the prognostic value of renal function relative to DSE findings in
2292 patients with known or suspected CAD, that were followed for a mean of 8 years. Is-
chemia during DSE is an independent predictor of mortality and hard cardiac events among the
entire strata of renal function. The degree of renal dysfunction is an additional determinant of
survival and hard events among patients with normal DSE as well as those with presence and
severity of wall motion abnormalities. The low risk period after a normal DSE is determined by
the presence and the severity of renal dysfunction.
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Abstract
Dobutamine stress echocardiography is a commonly used imaging modality for the diagnosis
of coronary artery disease and the detection of myocardial viability. The major limitations are that
it is operator dependent and that the analysis is subjective and qualitative resulting in interobserv-
er variability. It is also tedious and time consuming. Consequently, several quantitative approach-
es have been proposed, such as acoustic quantification and color kinesis but none of these has
proved to be fully quantitative. In this manuscript we describe the development of a new, quan-
titative technique based on tracking of both endocardium and epicardium providing information
of endocardial excursion and myocardial thickening, a crucial parameter of wall function evalua-
tion. Preliminary data indicate that the method is practical and feasible, but clinical trials are
required to prove whether it will improve the sensitivity and specificity of dobutamine stress
echocardiography.
Key words: dobutamine stress echocardiography, subjective, quantitative techniques, myo-
cardial thickening.
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Introduction
Two-dimensional echocardiography is a commonly used non-invasive method for the assess-
ment of left ventricular function. It provides precise information on both global and segmental
myocardial function by displaying endocardial motion and wall thickening.
Dobutamine stress echocardiography (DSE) is currently the leading non-invasive imaging
technique for the diagnosis and prognosis of coronary artery disease (CAD), the documentation
of myocardial viability and for long-term risk stratification [1].
However assessment of endocardial motion and wall thickening from two-dimensional echocar-
diography images largely depends on image quality and is both subjective, and qualitative [2].
This may result in interpretation variability.
Medical Background
Current limitations of Dobutamine Stress Echocardiography
The sensitivity of DSE for detecting CAD ranges from 81% to 85% with a similar specificity
range. These values are less in the presence of single vessel disease [2]. Nevertheless they are
similar to single-proton emission tomography (SPECT) and the other non-invasive stress imag-
ing modalities for both the detection of myocardial ischemia and viability (table 1) [2-7].
The subjective regional wall motion scoring system in DSE is based on using a five point score
(1= normokinesis; 2= mild hypokinesis; 3= moderate or severe hypokinesis; 4= akinesis; and
5= dyskinesis), dividing the left ventricle (LV) in 17 segments according to the recommendations
Table 1:   Comparison of sensitivities and specificities of different stress imaging modalities in
    detecting CAD (table 1A) or myocardial viability (table 1B). Concluding results from
    meta-analyses [1] [3-7].
Table 1A                            Ischemia detection
DSE SPECT CMR PET
Sensitivity 80-85% 83-95% 84-91% 93%
Specificity 82% 73% 80% 82%
Table 1B                            Viability Estimation
DSE SPECT CMR PET
Sensitivity 84% 84% 96% 100%
Specificity 81% 54-69% 86-100% 90%
DSE: dobutamine stress echocardiography
SPECT: single-photon emission computed tomography
CMR: cardiac magnetic resonance
PET: positron emission tomography
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of the American Society of Echocardiography [2] [8] [9]. A test is considered positive if new
wall motion abnormalities occur (i.e., if wall motion in any segment worsens by 1 grade during
testing, with the exception of akinesis becoming dyskinesis) [2] [8] [9].
However currently, DSE is an experience dependent technique subject to a high degree of
inter- and intra- observer variability. Signal dropout can be the cause of suboptimal images and
even lead to misdiagnosis in some patients. The majority of studies that support its use are mainly
derived from expert centres [10] and show the higher agreement for detection of three-vessel
disease (figure 1). Limitations occur in the performance of the test in less expert hands, as the
results obtained by stress echocardiograms result from subjective interpretation of wall mo-
tion[11] (table 2). Furthermore analysis of DSE data is tedious and time consuming.
Quantitative techniques
Quantitative techniques have been developed to provide objective quantitative and repro-
ducible information on global cardiac and regional wall function during stress [1] [2] [11-15].
The most important are: (1) image enhancement techniques including second harmonic im-
aging, endocardial border enhancement by transpulmonary contrast agents (Albunex, Laevo-
Table 2:   Stress echocardiography limitations
• Depends on image quality ( patient habitus / system requirements)
• Subjective interpretation
• Interobserver variability
• Lower diagnostic accuracy of single vessel CAD
• Follow-up difficult
Figure 1: Interinstitutional agreement on stress echocardiography for different degrees of coronary artery
disease [10].
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vist, BY 963) for improving cavity delineation and three-dimensional imaging with or without
contrast agents and (2) analytic software improvement, such as automatic contour techniques
(acoustic quantification, colour kinesis) and calculation techniques such as tissue Doppler myo-
cardial velocity derived parameters for analysis [1] [12] [15].
They provide better image quality and hence allow a more accurate analysis resulting in less
interobserver variability. However none of these methods takes into account the thickening of the
myocardium.
Color kinesis requires good to excellent 2D-image quality for tracking of the endocardium,
and encodes translational and rotational motion of the heart as endocardial motion. Its accuracy
is also affected by tachycardia and arrhythmias including atrial fibrillation and frequent ectopic
beats [11] [12].
Endocardial tracking based on tissue Doppler technique is a semi-quantitative technique that
can be used for the estimation of global ventricular function but has limitations in the presence of
regional wall motion abnormalities mainly because of low temporal resolution [12-14].
Consequently the development of more sophisticated quantitative techniques is needed. These
should take into account several criteria and should aim at an increase in sensitivity without loss
in specificity [11] (Table 3). Cardiac ultrasound is a reflection technique. In addition to the fast
motion of the heart, respiratory interferences pose additional problems in the analysis [17]. A
new quantitative technique ideally should take into account several parameters such as the shape
and the motion of both the endocardium and epicardium, providing important information on
myocardial thickening [11] [15] [17].
Automated coupled-contour and robust myocardium tracking
Coupled-contour and robust fusion for myocardial tracking is a newly developed analytic
software that aims to provide automated on-line quantitative data from images obtained in the
setting of DSE. It is designed to track both myocardial layers (i.e. epi- and endocardium) and
uses both excursion and thickening of the myocardium to detect wall function abnormalities.
Early automated contour detection techniques tracked only the endocardium in high-quality im-
ages off-line [18].
Preliminary data have shown an at least maintained sensitivity and increased specificity for the
detection of CAD. In a few preliminary clinical data standard DSE had a sensitivity of 88% and
Table 3 :   Criteria for an improved quantitative methodology to stress echocardiography
• Consider the thickening of myocardium
• Tracking both endo- and epi-cardium
• Feasibility/Reproducibility/Reliability of the performance of the algorithm used
• Low inter-observer variability
• Independence from heart rate and translational and rotational motion of heart
• High sensitivity without loss in specificity
• Reference values suitable for most candidates
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specificity 75%. When the automated on-line system was used, sensitivity was greater than 80%
(p: non-significant), for 80% specificity (p > 0.01). These findings are comparable with the
current DSE data, however, potentially there are improvements to be expected as the system is
less dependent on the quality of the images obtained.  Furthermore, while not a true speckle
tracking system, the system uses optical flow, and is capable of measuring rotation [16][19]
[21].
Technical considerations for quantitative wall assessment
The new software automatically classifies the myocardial segments as normal or abnormal
based on the endocardial excursion and thickening. This process consists of three steps: detec-
tion, tracking, and feature extraction and classification [17] [19] (figure 2).
Step1: Detection by Database-Guided Segmentation
The first step is the identification of the endocardium (figure 3). The application is based on
learned pattern recognition of several shape models. In general there are several different shape
models [17] [19] (figure 4).This is done using a technique called Database-Guided Segmenta-
tion [17] [19]. As the name implies, segmentation is guided by a database of cases which at-
tempts to "teach" the system how to detect and segment a border. This is done by first creating a
large database of cases which represent the wide variety of patients and diseases types typically
tested in coronary artery disease. Each of these cases is then contoured by one or more experts,
giving the basis of "learning" to the system. The learning set of the described system is based on
data from 345 DSE tests delivered from several centres, scored in Erasmus MC, Rotterdam,
The Netherlands. Each segment has a score 1-5 (1=normal, 2=hypokinetic, 3=akinetic, 4=dys-
kinetic, 5=aneurysmal). From this data-base and domain knowledge of the individual LV con-
tours, a reference set of LV shapes is created. Each reference shape may be the result of aver-
aging shapes of many studies and is referred to as the "learning set". These shapes are subse-
quently used for matching and recognition of LV contours and shapes during a DSE study [17]
[19] [22].
Step 2: Tracking by Robust Information Fusion
The second step of the process is to track the border. This is called Robust Information
Fusion [17] [19], and uses learned motion models of the heart to track the endocardium throughout
the heart cycle. That is, once the endocardial border is identified in one frame, it needs to be
tracked to all of the other frames in the heart. This is done by first recognizing that the specific
location of the endocardium as identified by the system has some level of uncertainty (figure 5).
These measurement uncertainties stem for the echocardiograms from the acoustic drop-out (where
tissue surface is parallel to ultrasound beam) [19-21, 23]. Tracking is performed by obtaining
independently from each model a motion estimate and its uncertainty through optical flow [17]
[19]. These models are again learned from the database of previous studies, just as detection
models were learned for detection.
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Figure 2: The principle of automatic myocardial wall tracking. A (step 1: Border detection): Dots in the
user defined area represent endocardial detection. B (step 2: Border tracking): Dots in the user defined
area represent epi- and endocardial tracking. C (step 3: Feature extraction and classification in a different
patient than A and B): Dots are interconnected with lines at both the epi-and endocardium to generate
contours used for image quantification.
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Figure 3: A: The first step is the localization and detection of the endocardium by using multiple LV
frames. B: Dots depict the epi- and endocardial border.
Figure 4: Images of learning sets showing different long-axis (A) and short-axis (B) left ventricular shape
models. The whole application is based on pattern recognition using many different shapes of left ventricles
learned from patient studies. Each image is an average of several cross-sections obtained from different
DSE studies. Dots interconnected by lines represent the endocardium.
A
B
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In echocardiographic images the epicardium is often more difficult to identify than endocardi-
um by a software algorithm because of the high-reflecting surrounding structures. So for epicar-
dium tracking, this system utilizes a double contour that can propagate information from the
endocardium to guide the localization of the epicardium (or vice versa), and can better follow its
location during the cardiac cycle and reduce the chance of crossing [17] [19]. For this purpose
it uses the apex, the papillary muscles and the basal end of septum as landmark points that can be
automatically assigned [17].This coupled contour approach integrates more spatial information,
thus can provide more robust tracking of the endocardium and epicardium (figure 6) and permits
accurate border motion tracking [17] [19] [20].
Step 3: Feature extraction and classification
Feature extraction and classification is the third step of the processing of the data. Once the
endocardial and epicardial border have been detected and tracked, a coupled-contour is de-
rived, from which the system extracts a few global (involving the whole LV) and local (involving
individual segments visible in the image) numerical features for quantitation [17] [19]. These
Figure 5: These apical four chamber views are obtained from two different patients undergoing a DSE
study. The magnitude of the ellipses shows the uncertainties in motion estimation of the dots representing the
endocardium in these examples. The larger the ellipse the bigger the uncertainty. In the panel A the uncertainties
are largest in the distal/septal area while in panel B they are largest in the apex. This means that the system
cannot accurately recognize the exact location of a certain landmark point in the next frame.
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features derive from volume changes (segmental volumes by Simpson's rule), velocity, timing,
radial strain (thickening) and circumferential strain [17, 19-24] (figure 7).
For each segment of a DSE study, a subset of relevant features is selected for classification.
Statistical correlation methods of small number of features are applied for proper feature collec-
tion from the DSE study.  Using a small number of features not only improves performance time
but also results in a more robust and versatile learning set [17] [19]. The collected features are
the classifiers and will provide the final automatic quantification.
Figure 7 depicts the diagram of system processing, from data to final quantitative features.
Clinical Implications
Coronary artery disease is one of the leading causes for mortality and morbidity. DSE could
become the primary test as an everyday clinical tool, if a quantitative technique could substitute
the eyeball assessment of regional wall motion abnormalities. The above mentioned technique
seems promising as it aims to improve the accuracy and reduce the inter- and intra-observer
variability of DSE. It is the first robust automatic coupled-contour myocardial tracking technique
that utilizes the thickening of the myocardium during systole. However the system may not accu-
rately recognize the exact location of a certain landmark point in subsequent frames. Moreover
the training set of the proposed image processing technique is set by "expert" results which in turn
Figure 6: The second step is coupled motion tracking of endo- and epicardial contours. A 4-chamber
view is shown as an example. The tracking is done by matching (fusing) the information gained by the
learning set of the systems subsequent steps. Then the continuous contour estimation of each subsequent
frame follows as shown in figure 5.
KARAGIANNIS et al12
are subject to a certain degree of observer variability. These could present possible limitations of
the proposed system. It remains to be seen whether this image processing technique will be
feasible and will provide an accurate interpretation of wall motion abnormalities.
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Abstract
Dobutamine stress echocardiography (DSE) has a modest sensitivity in single vessel coronary
artery disease (CAD).  Aim of this study was to assess the additional diagnostic value of new or
worsening wall motion abnormalities (NWMA) during the recovery phase after acute adminis-
tration of beta-blockers.
The study population consisted of 200 patients (mean age: 59±11 years; 144 men), who
underwent DSE. Images were acquired at rest, low dose, peak dose, and recovery phase.
Patients received intravenous metoprolol (1-5 mg/min). The dose was adjusted to achieve a
recovery heart rate, within a 10% range of the resting heart rate. Coronary angiography was
performed within 2 months.
Inducible new wall motion abnormalities were observed in 168 (84%) patients at peak stress.
An additionnal 14 patients (7%) experienced NWMA during the recovery phase. CAD was
detected in 182 patients (86 had single vessel CAD).  Sensitivity, specificity and accuracy of
DSE were 88%, 65%, 73% at peak stress and 97%, 65%, 74% at recovery. Sensitivity was
Running head: Detection of coronary artery disease during recovery phase of stress echocardiography
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particularly higher during recovery than peak stress in patients with single vessel CAD (98% vs.
81%, p<0.001)
The assessment of wall motion abnormalities during the recovery phase after acute beta block-
ade improves sensitivity of DSE particularly in patients with single vessel CAD.
Text
Introduction:
Dobutamine stress echocardiography (DSE) is a useful non-invasive technique for evaluation
of coronary artery disease (CAD). 1,2 One limitation of the DSE is the modest sensitivity in
patients with single vessel CAD1. Some studies have suggested that wall motion abnormalities
may develop in the recovery period after beta-blocker administration3. However, it is not yet
established whether acute beta-blocker administration improves the accuracy of DSE.
The aim of our study is to estimate the additional diagnostic value of new or worsening wall
motion abnormalities (NWMA) during the recovery phase of DSE after receiving acute beta-
blockade compared to findings at peak and using coronary angiography as reference.
Methods:
Patients: We prospectively studied 200 consecutive patients with known or suspected CAD
with DSE between March 2003 and April 2004. Patients received metoprolol intravenously at
peak stress, irrespective of image interpretation at peak stress. Coronary angiography was per-
formed within 2 months. Patient characteristics are presented in Table 1.
Dobutamine stress echocardiography: The DSE protocol was approved by the Hospital
Ethical Committee and was performed in accordance with well-established protocols4,5,6. Stud-
ies were performed using a Philips Sonos 5500 system. Patients underwent a resting two-dimen-
sional echocardiographic examination from the standard apical and parasternal views. Images
were recorded on videotape and also digitized for comparison of different stages. Dobutamine
was then administered intravenously by infusion pump, starting at 5 mg/kg/min for 3 minutes,
followed by 10 mg/kg/min for 5 minutes and increasing by 10 mg/kg/min every 3 minutes to a
maximum of 40 mg/kg/min (stage 5), and continued for 6 minutes. The dobutamine infusion was
stopped if a target heart rate (85% of a theoretic maximal heart rate (men: (220 – age) x 85%;
women: (200 – age) x 85%) was achieved. If the target heart rate was not achieved and patients
had no symptoms or signs of ischemia, atropine (starting with 0.25 mg, increased to a maximum
of 2.0 mg) was given intravenously at the end of stage 5 while the dobutamine administration was
continued. During the test, a 12-lead ECG was recorded every minute. Blood pressure was
measured every 3 minutes. Metoprolol was administered (1,0 to 5,0 mg) intravenously accord-
ing to heart rate response and systolic blood pressure, and after peak stress images were ac-
quired to achieve a recovery phase, defined as heart rate within 10% range of resting heart rate.
The criteria for stopping the test were: (1) achievement of the target heart rate (2) severe and
extensive NWMA, (3) horizontal or downsloping ST depression of ≥0.2 mV measured 80 ms
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Demographics
Males 144 (72%)
Females 54 (27%)
Age 59–11
Cardiovascular History and
cardiac risk factors
Hypertension 70 (35%)
Heart Failure 44 (22%)
Diabetes Mellitus 32 (16%)
Previous Myocardial Infarction 102 (51%)
Dyslipidemia 102 (51%)
Smoking 50 (25%)
Cardiac Medication
ACE-inhibitors 90 (45%)
Aspirin 52 (26%)
Statins 44 (22%)
â-blockers 128 (64%)
Nitrates 112 (56%)
Diuretics 44 (22%)
Digoxin 12 (6%)
Table 1: Study population characteristics
Patient Characteristics
after the J point, or ST-segment elevation of ≥0.2 mV in the absence of Q waves, (4) symptom-
atic decline in systolic blood pressure of more than 40 mmHg, or a systolic blood pressure ≤ 90
mmHg, (5) hypertension (blood pressure >240/140 mmHg), (6) the occurrence of sustained
cardiac arrhythmias, (7) severe angina pectoris, and (8) intolerable adverse effects considered to
be the result of dobutamine or atropine. Two experienced investigators performed off-line as-
sessment of echocardiographic images without knowledge of the patient’s clinical and coronary
angiography data, but with knowledge of the doses of dobutamine and atropine used. The results
of DSE were considered positive if NWMA occurred (i.e., if wall motion in any segment wors-
ened by ≥1 grades during the test, with the exception of akinesis becoming dyskinesis). The
extent and location of ischemia were evaluated and a wall-motion score index (total score divid-
ed by the number of segments scored) was calculated, at rest, during peak stress, and during the
recovery phase. Digital screen format was used to compare images. When there was disagree-
ment between the two assessors, a third investigator viewed the images without knowledge of
the previous assessments, and a majority decision was reached.
Coronary angiography: The presence of CAD was established by standard quantitative
coronary angiography using the Judkins technique. A luminal diameter stenosis > 70% in a major
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epicardial vessel was considered significant. Multivessel CAD was defined by the presence of
significant stenosis of two or three vessels, or more than 50% stenosis of the left main stem.
Statistical analysis: Results are expressed as mean value ± SD. The t-test was used for
continuous variable and chi –square test was used for categorical variables. A two-tailed p<0.05
was considered significant. Furthermore 2 x 2 tables with weight k statistics were used for com-
parisons between coronary angiography results and DSE results and for inter-observer agree-
ment. On the basis of Fleiss’s classification 7 k values < 0.4, between 0.4 and 0.75, and > 0.75
were considered to indicate poor, fair to good, and excellent agreement respectively. Multivari-
ate logistic regression was used to investigate the predictive value of NWMA in the recovery
phase and peak stress of DSE for single vessel disease patients adjusting for age, gender, previ-
ous MI, and congestive heart failure.
Sensitivity, specificity, diagnostic accuracy and predictive values were calculated according to
standard definitions. At last intra-observer agreement was calculated by Spearman correlation.
Results: CAD was detected in 182 patients, while in 28 no significant abnormalities were
detected. Angiographically 86 patients had single vessel CAD and 52 had 2-vessel CAD and 44
The hemodynamic data of DSE are presented in table 2. Rest wall motion abnormalities were
observed in 160 patients, while NWMA at peak stress were assessed in 168 patients. During
the recovery phase NWMA were assessed in an additional 14 (7%) patients.
Accuracy of DSE for diagnosis of CAD:
At peak stress there were 6 false-positive and 21 false-negative results. In the majority of
patients target heart rate was achieved after administration of atropine at peak stress, as 64% of
Table 2: Results and Hemodynamic data during DSE
DSE results
(peak stress) no CAD 32 (16%)
Single-vessel
disease 82 (41%)
Multi-vessel
disease 86 (43%)
rest    peak peak+atropine Recovery
HR (beats/min) 69–13 107–21 132–13 88–13
SBP (mmHg) 126–22 130–26 129–27 121–23
DBP (mmHg) 71–12 68–14 68–16 68–13
rate-pressure
product
(mmHg/min) 8694–286         13910 – 546 17028 – 351 10648–299
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them were already on chronic beta-blockade that was not stopped prior to the study. The sen-
sitivity, specificity and accuracy of DSE for detection of CAD, and sensitivities for single and
multivessel disease at peak and recovery are summarized in table 3. The sensitivity at peak stress
for the detection of CAD was 88% (95% CI 84% to 93%) and specificity 65% (95% CI 59%
to 71%). For single-vessel disease the sensitivity at peak stress was 81% (95% CI 75% to
87%) (Figure 1) and for multivessel disease was 85% (95% CI 80% to 90%) (Figure 2). The
overall diagnostic accuracy of DSE at peak stress for the detection of CAD was 73% (95% CI
66% to 79%). For detection of single-vessel or multivessel disease the respective percentages
were 87% (95% CI 82% to 92%) and 89% (95% CI 85% to 93%).
When recovery images were analyzed the sensitivity for the detection of CAD increased to
97% (95% CI 94% to 99%), while specificity remained unchanged. The increase in sensitivity
was especially prominent in patients with single-vessel disease to 98% (95% CI 96% to 100%)
(Figure 1). For multivessel disease the sensitivity increased to 89% (95% CI 85% to 94%)
(Figure 2).
Patients on chronic beta-blockade did not show any difference in sensitivity compared to the
group that did not receive chronically beta-blockers.
Using k-statistics, the detection of agreement between coronary angiography results and DSE
results increased from 0.7 at peak stress to 0.85 at the recovery phase, indicating a good agree-
ment of DSE with the angiographic findings in the recovery phase.
Intra-observer and inter-observer variability: We observed good intra-observer agree-
ment (correlation between two measurements of same observer) for rest (r=0.90), low (r=0.93),
peak (r=0.88), and recovery images (r=0.88) (all p<0.001). Moreover the global inter-observ-
er agreement was 88%.
Response to beta-blockade: After metoprolol injection in 14 patients the diagnosis of CAD
changed. In 10 patients NWMA could be detected which had single vessel disease, in 3 patients
Table 3: Sensitivity, specificity and accuracy of DSE for detection of CAD, and sensitivities for
  single and multivessel disease at peak and recovery.
   Sensitivity    Specificity      Accuracy
peak    recovery peak   recovery peak    recovery
CAD overall
(peak 168pts
vs recovery 182pts) 88% 97%       65%   65% 73% 74%
Single-vessel disease
(peak 82pts
vs recovery 92 pts) 81% 98%
Multivessel disease
(peak 86pts
vs recovery 90pts) 85% 89%
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Figure 1: Sensitivity (sens) (p<0.001), specificity (spec) (p=0.05), diagnostic accuracy (acc) (p:NS),
positive predictive value (PPV) (p:NS) and negative predictive value (NPV) (p<0.01) for single-vessel
disease at peak and recovery.
Figure 2: Sensitivity (sens) specificity (spec), diagnostic accuracy (acc) positive predictive value (PPV)
and negative predictive value (NPV) for multi-vessel disease at peak and recovery (all p: NS).
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the diagnosis was changed from single to multivessel vessel disease and in 1 additional patient the
diagnosis changed from normal to multivessel disease (Figure 3). All patients that showed NWMA
at peak stress had persisting abnormalities after acute beta-blockade. Multivariate regression
analysis showed that, recovery phase results in total and NWMA in the recovery phase were the
only independent predictors for single vessel disease patients (odds ratio [OR] 0.14, 95% CI
0.07 to 0.28 and 6.24, 95% CI 2.61 to 14.9 respectively).
Discussion:
Dobutamine stress echocardiography is widely used for the detection of CAD, by observa-
tion of NWMA1. However the test has a reduced sensitivity for the detection of single vessel
disease1,2. The sensitivity of DSE for the detection of single vessel disease ranges from 40% to
92% and for multi-vessel disease from 65% to 83% while specificity remains unchanged8,9,10.
Our study showed that wall motion abnormalities assessment during the recovery phase after
acute beta-blockade increased the sensitivity for the detection of single vessel disease signifi-
cantly from 81% to 99% (p<0.001) while the specificity was marginally decreased. More spe-
cifically the decrease in specificity was of borderline statistical significance (p=0.05), a trend that
could be regarded as potential limitation of our study; although it could be related to the small
number of normal subjects and the high prevalence of disease of the study population. Also in
Figure 3: Single- (SVD) and multi- (MVD) vessel disease patients with new wall motion abnormalities at
recovery (p<0.001 and p: NS respectively)
KARAGIANNIS et al24
additional 3 patients the diagnosis was changed from single vessel to multivessel disease and in
one from normal to multivessel disease. Moreover during the recovery phase the value of rate-
pressure product, as a measure of oxygen consumption rate, was less than its value at peak
stress, but more than the value at rest. This indicates a prolonged ischemic effect of dobutamine
during the recovery phase.
    There is limited knowledge and utilization of regional wall motion abnormalities that contin-
ue at recovery phase or even more NWMA that present in the recovery phase of dobutamine
stress echocardiography.
    Dobutamine exerts its effect by stimulation of â1, â2, and Æ1-adrenergic receptors11. Acute
â-blockade interacts with dobutamine â1 and â2 receptors leaving unopposed Æ1-adrenergic
vasoconstriction12 and therefore leading to reduction of coronary flow reserve13. So myocardial
ischemia could result from increased vasoconstriction and that could explain the paradoxical
enhancement of wall motion abnormalities at the recovery phase.
Another possible explanation of our findings is that at the recovery phase we could better
visualize the NWMA that already existed at peak stress but were masked by hyperdymanic
contraction of mid- and epicardial layers. This is especially true in single-vessel disease patients
in contrast to multivessel disease patients where sensitivity is higher and NWMA are more pro-
found after dobutamine administration. So the sensitivity increase in single vessel disease patients
is higher as the baseline sensitivity is less than in multivessel disease.
There is one previous study that showed that the duration of wall motion abnormalities in the
recovery phase was correlated to the extent of CAD14. Actually this study showed that the
persistence of wall motion abnormalities in the recovery phase of dobutamine stress echo was
correlated to the severity of CAD, irrespective of the prior administration of beta-blockade
infusion to fasten the time to recovery.
In another study it was demonstrated that injection of beta-blockers at the peak dose of DSE
might enhance regional wall abnormalities and increase the sensitivity of the combined peak plus
metoprolol images especially in single-vessel disease patients3. Our results coincide with the
above study with even better improvement in sensitivity of the recovery phase assessment only,
and not of a combination of peak stress plus recovery phase images as the aforementioned study.
Clinical implications: Although there is a protective effect of beta-blockade in relieving
myocardial ischemia15,16, paradoxically, we observed that a significant percentage of patients
developed new wall motion abnormalities during the recovery phase.
In conclusion observation and scoring of individual segments at recovery phase, as part of the
regular DSE scoring, in patients that receive acute beta-blockade at peak stress, could add to
the better assessment of ischemia in CAD patients.
Refferences:
1. Picano E. Stress echocardiography. Expert Rev Cardiovasc Ther. 2004 Jan; 2(1): 77-88
2. Labib SB, Goldstein M, Kinnunen PM, Schick EC. Cardiac events in patients with negative maximal
versus negative sub maximal dobutamine echocardiograms undergoing non-cardiac surgery: impor-
tance of resting wall motion abnormalities. J Am Coll Cardiol. 2004 Jul 7; 44(1): 82-7.
3. Mathias W Jr, Tsutsui JM, Andrade JL, Kowatsch I, Lemos PA, Leal SM, Khandheria BK, Ramires
ENHANCED SENSITIVITY OF DOBUTAMINE STRESS ECHOCARDIOGRAPHY BY OBSERVING WALL MOTION
ABNORMALITIES DURING THE RECOVERY PHASE AFTER ACUTE BETA BLOCKER ADMINISTRATION
25
JF.Value of rapid beta-blocker injection at peak dobutamine-atropine stress echocardiography for de-
tection of coronary artery disease. J Am Coll Cardiol. 2003 May 7; 41(9): 1583-9
4. Shiller N, Shah P, Crawford M, et al. Recommendations for quantitation of the left ventricle by two –
dimensional echocardiography. J Am Soc Echocardiogr 1989; 2:358-67
5. Armstrong WF, Pellikka PA, Ryan T, et al. Stress echocardiography: recommendations for performance
and interpretation of stress echocardiography. Stress Echocardiography Task Force of the Nomencla-
ture and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr.
1998;11(1):97-104.
6. Edwards WD, Tajik AJ, Seward JB. Standardized nomenclature and anatomic basis for regional tomo-
graphic analysis of the heart. Mayo Clin Proc. 1981;56(8):479-497.
7. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York: Wiley, 1981.
8. Yuda S, Fang ZY, Leano R, Marwick TH.    Is quantitative interpretation likely to increase sensitivity of
dobutamine stress echocardiography? A study of false-negative results. J Am Soc Echocardiogr. 2004
May; 17(5): 448-53
9. San Roman JA, Serrador A, Ortega JR, Medina A, Fernandez-Aviles F. Diagnostic accuracy of a new
shorter dobutamine infusion protocol in stress echocardiography. Heart 2003 Sep; 89(9): 1089-90
10. Elhendy A, MD, PhD, Ron T. van Domburg, Msc, PhD, Jeroen J. Bax, MD, PhD et. al. Optimal criteria for
the diagnosis of coronary artery disease by dobutamine stress echocardiography. Am J Cardiol 1998;82:
1339-1344
11. Leier CV, Unverferth DV. Drugs five years later. Dobutamine. Ann Intern Med. 1983;99(4):490-496.
12. Adel R. Shehata MB BCh, Linda D. Gillam MD, Victor A. Mascitelli MD, et al. Impact of acute propra-
nolol administration on Dobutamine-induced myocardial ischemia as evaluated by myocardial perfu-
sion imaging and echocardiography. Am J Cardiol 1997;80:268-272
13. Frishman W, Sonnenblick EH. Beta-adrenergic blocking drugs. In:Schlant RC, Alexander RW. Hurst‘s.
The Heart: Arteries and Veins. 8th edition.McGraw-Hill, Inc., 1994:1271-90
14. Tsoukas A, Ikonomidis I, Cokkinos P, Nihoyannopoulos P. Significance of persistent left ventricular
dysfunction during recovery after dobutamine stress echocardiography. J Am Coll Cardiol. 1997 Sep;
30(3): 621-6
15. Bath C, Ojile M, Pearson AC, Labovitz AJ. Ultra short-acting intravenous â-adrenergic blockade as add-
on therapy in acute unstable angina. Am Heart J 1991;121:782-8
16. Labovitz AJ, Bath C, Castello R, et al. Attenuation of myocardial ischemia during coronary occlusion by
ultrashort-acting beta-adrenergic blockade. Am Heart J 1991;21:1347-52
Myocardial Viability Estimation During
Recovery Phase of Stress
Echocardiography After Acute Beta-
Blocker Administration
Stefanos E. Karagiannis1 MD, Harm H.H. Feringa1 MD, Jeroen J. Bax2 MD,
Abdu Elhendy MD3, Martin Dunkelgrun1 MD, Radosav Vidakovic MD1, SE Hoeks MSc1,
Ron van Domburg1 PhD, Roelf Valhema MD4, Dennis V. Cokkinos5 MD,
Don Poldermans MD1
1 Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
2 Department of Cardiology, Leiden University, Leiden, The Netherlands
3  Department of Cardiology, University of Omaha, Nebraska, USA
4
 Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
5 1st Department of Cardiology, Onassis Cardiac Surgery Centre, Athens, Greece
Eur J Heart Fail. 2007 Apr; 9(4):403-8
KARAGIANNIS et al28
29MYOCARDIAL VIABILITY ESTIMATION DURING RECOVERY PHASE OF STRESS ECHOCARDIOGRAPHY AFTER
ACUTE BETA-BLOCKER ADMINISTRATION
29
3CHAPTER
Corresponding author:
Prof. Dr. Don Poldermans, Department of Cardiology, Room H 921Erasmus MC, Dr. Molewaterplein 40,
3015 GD Rotterdam, the Netherlands,
Fax: +31104634957
Tell: +31104639222
E-mail: d.poldermans@erasmusmc.nl
Myocardial Viability Estimation During
Recovery Phase of Stress
Echocardiography After Acute Beta-
Blocker Administration
Stefanos E. Karagiannis1 MD, Harm H.H. Feringa1 MD, Jeroen J. Bax2 MD,
Abdu Elhendy MD3, Martin Dunkelgrun1 MD, Radosav Vidakovic MD1, SE Hoeks MSc1,
Ron van Domburg1 PhD, Roelf Valhema MD4 , Dennis V. Cokkinos5 MD,
Don Poldermans MD1
1 Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
2 Department of Cardiology, Leiden University, Leiden, The Netherlands
3  Department of Cardiology, University of Omaha, Nebraska, USA
4
 Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
5 1st Department of Cardiology, Onassis Cardiac Surgery Centre, Athens, Greece
Abstract
Background: Myocardial viability assessment in severely dysfunctional segments by dob-
utamine echocardiography (DSE) is less sensitive than nuclear scanning.
Aim: To assess the additional value of recovery phase of DSE after acute beta blocker
administration for identifying viable myocardium.
Methods: The study population included 49 consecutive patients with ejection fraction
(LVEF)≤35%. All patients underwent DSE evaluation at low-high dose and during recovery
phase, and dual-isotope single photon emission tomography (DISA-SPECT) evaluation for via-
bility of severely dysfunctional segments. Patients with ≥4 viable segments were considered
viable. Coronary revascularization followed within 3 months in all. Radionuclide LVEF was per-
formed prior and twelve months after revascularization.
Results: Viability with DISA-SPECT was detected in 463 (59%) segments, while 154
(19.7%) segments presented as scar. The number of viable segments increased from 415 (53%)
at DSE to 463 (59%) at DSE and recovery and viable patients increased from 43 to 49 respec-
Running head: Viability estimation during recovery phase of stress echocardiography Word count: 2797
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tively. LVEF improved ≥5% in 27 patients. Multivariate regression analysis showed that, DSE
with recovery phase was the only independent predictor of ≥5% LVEF improvement after re-
vascularization (OR 14.6, CI 1.4-133.7).
Conclusion: In this study we demonstrate that the recovery phase of DSE has an increased
sensitivity for viability estimation compared to low-high dose DSE.
Keywords: Dobutamine Stress Echocardiography, recovery phase, viability.
Introduction
Coronary artery disease (CAD) is one of the major causes of left ventricular (LV) dysfunction
and is one of the leading causes of mortality and morbidity. So far the predictive value of dob-
utamine stress echocardiography (DSE) for the recovery of LV function after revascularization is
less compared to nuclear scan techniques. As these techniques mainly focus on finding islands of
viable tissue, DSE focuses on segmental function of LV; a feature that explains the lower sensitiv-
ity of the test compared to other imaging techniques, with a slightly better specificity [1]. The
studies published to date on the use and importance of DSE in the evaluation of myocardial
viability combine various subgroups of patients. [1][2] A complete test, compared with only low-
dose images, is more accurate in predicting LV functional recovery after revascularization. This is
ascribed to the ability of full-dose dobutamine to recognize more accurately the biphasic and
ischemic response.[1] These ischemic responses may be missed if only a low-dose dobutamine
protocol is performed. Furthermore it is shown [3] that recovery phase of DSE in patients re-
ceiving acute beta-blockade, after peak images are obtained, is important in identifying further
ischemia. It is demonstrated that injection of beta-blockers at the peak dose of DSE might
enhance regional wall abnormalities and increase the sensitivity of the combined peak plus meto-
prolol images [3].  As treatment modalities for LV dysfunction and concomitant heart failure
include revascularization we have to clearly identify patients with dysfunctional but viable myo-
cardium. Nevertheless the evaluation of the recovery phase of DSE for viability estimation is not
yet studied. The aim of our study is to assess the additional value of viability estimation during the
recovery phase of DSE after receiving acute beta-blockade compared to findings at low-high
dose DSE and using dual-isotope single photon emission tomography (DISA-SPECT)  as refer-
ence.
Methods
Patient population
The study population included 49 consecutive patients with known or suspected CAD who
were referred at the Thoraxcenter (Rotterdam, the Netherlands) between January 2004 and
January 2005. Patients with ejection fraction ≤35% were enrolled. All the patients underwent
DSE and DISA-SPECT examination for evaluation of viability. A revascularization procedure
followed within 3 months according to the discretion of the referring physician discretion, who
was aware of the tests results.
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Radionuclide ventriculography was also performed within one month before and twelve months
after the revascularization procedure. The local medical ethics committee approved the study
protocol. Patients gave an informed consent to undergo the study.
Radionuclide ventriculography
Radionuclide ventriculography was performed at rest with the patient in supine position after
administration of 740 MBq of Tc-99m. Images were acquired with a small field-of view gamma
camera (Orbiter, Siemens Corp., Erlangen, Germany) oriented in the 45° left anterior oblique
position with a 5° to 10° caudal tilt. LV ejection fraction was calculated by standard methods
(Odyssey VP, Picker, Cleveland, Ohio).
Dobutamine stress echocardiography
The DSE protocol was approved by the Hospital Ethical Committee and was performed in
accordance with well-established protocols.[4][5] Studies were performed using a Sonos 5500
imaging system (Phillips Medical Systems, Eindhoven, The Netherlands). Patients underwent a
resting two-dimensional echocardiographic examination from the standard apical and paraster-
nal views. Images were recorded on videotape and also digitized for comparison of different
stages. Dobutamine was then administered intravenously by infusion pump, starting at 5 mg/kg/
min for 3 minutes, followed by 10 mg/kg/min for 5 minutes and increasing by 10 mg/kg/min every
3 minutes to a maximum of 40 mg/kg/min (stage 5), and continued for 6 minutes. The dob-
utamine infusion was stopped if a target heart rate (85% of a theoretic maximal heart rate (men:
(220 – age) x 85%; women: (200 – age) x 85%) was achieved. If the target heart rate was not
achieved and patients had no symptoms or signs of ischemia, atropine (starting with 0.25 mg,
increased to a maximum of 2.0 mg) was given intravenously at the end of stage 5 while the
dobutamine administration was continued. During the test, a 12-lead ECG was recorded every
minute. Blood pressure was measured every 3 minutes. Metoprolol was administered (1,0 to
5,0 mg) intravenously after peak stress images were acquired and according to heart rate re-
sponse and systolic blood pressure, to achieve a recovery phase, defined as heart rate within
10% range of resting heart rate.
The criteria for stopping the test were: (1) achievement of the target heart rate (2) severe and
extensive NWMA, (3) horizontal or downsloping ST depression of ≥0.2 mV measured 80 ms
after the J point, or ST-segment elevation of ≥0.2 mV in the absence of Q waves, (4) symptom-
atic decline in systolic blood pressure of more than 40 mmHg, or a systolic blood pressure ≤ 90
mmHg, (5) hypertension (blood pressure >240/140 mmHg), (6) the occurrence of sustained
cardiac arrhythmias, (7) severe angina pectoris, and (8) intolerable adverse effects considered to
be the result of dobutamine or atropine. Two experienced investigators performed off-line as-
sessment of echocardiographic images without knowledge of the patient’s clinical and coronary
angiography data, but with knowledge of the doses of dobutamine and atropine used. Interob-
server and intraobserver agreement for analysis of DSE studies were reported previously (92%
and 94%, respectively)[6]. Regional function was scored according to a 16 segment, five point
scoring model: 1, normal; 2, mildly hypokinetic; 3, severely hypokinetic; 4, akinetic; and 5,
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dyskinetic. Wall-motion score index (WMSI) (total score divided by the number of segments
scored) was calculated, at rest, low dose, during peak stress, and during the recovery phase.
Myocardial viability was assessed only in severely dysfunctional segments; 4 types of wall
motion responses were observed: (1) biphasic pattern: improvement of wall motion at 5, 10, or
20 mg/kg/min dobutamine with worsening at higher dosages; (2) worsening; (3) sustained im-
provement; and (4) no change. Severely dysfunctional segments exhibiting a biphasic, sustained
improvement, or ischemic response were considered viable, whereas segments with unchanged
wall motion were considered scarred. The same criteria were applied when recovery phase
images were added to the evaluation.
A patient was considered to have viable myocardium in the presence of ≥4 viable segments
and as non-viable in the presence of ≥4 viable segments [7]. This definition is based on previous
work with receiver operator characteristic curve analysis that showed that recovery of function
may be predicted in the presence of ≥4 viable segments [7].
Digital screen format was used to compare images. When there was disagreement between
the two assessors, a third investigator viewed the images without knowledge of the previous
assessments, and a majority decision was reached.
Dual-isotope single photon emission tomography
DISA-SPECT imaging using technetium-99m tetrofosmin (perfusion) and fluorine-18 fluoro-
deoxyglucose (metabolism) tracers was performed as previously described [8] The left ventricle
was divided into 16 segments (6 basal—anterior, anterolateral, inferolateral, inferior, inferosep-
tal, and anteroseptal), 6 distal, and 4 apical segments, corresponding to echocardiographic seg-
ments. Segmental tetrofosmin and FDG uptake were scored by 1 experienced observer (blind-
ed to echo data) using a 4-point grading system (0, normal;1, mildly-moderately reduced; 2,
severely reduced;and 4, absent). According to this scoring model, criteria of viability were (1)
normal perfusion and FDG uptake, (2) concordantly mildly-moderately reduced perfusion and
FDG uptake, or (3) reduced perfusion with preserved or increased FDG uptake (mismatch).
Segments with severely reduced or absent perfusion and concordantly reduced (or absent) FDG
uptake was considered scar tissue.
Statistics
Results are expressed as mean value  SD. The t-test was used for continuous variable and chi
–square test was used for categorical variables. A two-tailed p<0.05 was considered significant.
Kappa statistics were used for agreement between DISA-SPECT and DSE. On the basis of
Fleiss’s classification [9] k values < 0.4, between 0.4 and 0.75, and > 0.75 were considered to
indicate poor, fair to good, and excellent agreement respectively. A McNemar test was applied
to study the difference in DSE results with and without recovery phase evaluation, controlled by
nuclear testing results.
Multivariate logistic regression was used to investigate the predictive value of viability in
DSE+recovery phase, versus low-high DSE, for global left ventricular improvement after revas-
cularization, adjusting for age, gender, previous MI, and congestive heart failure [10].
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Sensitivity, specificity, diagnostic accuracy and predictive values were calculated according to
standard definitions.
Results
The patients’ clinical characteristics are presented in Table 1. The patients’ medications were
not discontinued during the study. All patients were submitted for revascularization; 40 under-
went percutaneous transluminal coronary angioplasty and 9 coronary artery by-pass grafting. In
total 27 patients showed a ≥5% increase in left ventricular ejection fraction 12 months after
revascularization.
Patient Characteristics and Hemodynamic response
During DSE the heart rate increased significantly from rest to peak stress. Test end point was
target heart rate and was reached in 94% of patients. Atropine was added at peak stress in 31
patients as the majority was on chronic beta-blockade that was not stopped prior to the study.
Table 1: Study population characteristics
Demographics
Males
35 (72%)
Females 14 (28%)
Age 59–11
Cardiovascular History and
cardiac risk factors
Hypertension 17 (35%)
Heart Failure 11 (22%)
Diabetes Mellitus 8 (16%)
Previous Myocardial Infarction 25 (51%)
Dyslipidemia 25 (51%)
Smoking 12 (25%)
Previous PCI 27 (55%)
Cardiac Medication
ACE-inhibitors 22 (45%)
Aspirin 13 (26%)
Statins 11 (22%)
â-blockers 31 (64%)
Nitrates 27 (56%)
Diuretics 11 (22%)
Digoxin 3 (6%)
Characteristics in  49 patients
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The mean maximal dobutamine dose was 38 ± 8 mcg/kg/min. All patients received metoprolol
(1,0 to 5,0 mg) intravenously after peak stress images were acquired and according to heart rate
response and systolic blood pressure. Side effects included hemodynamically stable sustained
ventricular tachycardia (>10 complexes) in 1 (2%) patients, non-sustained ventricular tachycar-
dia (<10 complexes) in 2 (3%) patients, atrial fibrillation in 2 (3%) patients and severe hypoten-
sion (decrease of systolic blood pressure >40mmHg) in 1 (2%) patients. No myocardial infarc-
tion or ventricular fibrillation was recorded during or attributed to DSE.
The rate pressure product values at rest, low, peak and recovery were 8694 ± 286, 13910 ±
546, 17028 ± 351 and 10648 ± 299 respectively. WMSI at rest was 2.05 ± 0.91, at low dose
1.83± 0.79, at peak dose 1.90 ± 0.83 and at recovery phase 2.15 ± 0.94.
The number of viable segments increased from 415 (53%) at DSE to 463 (59%) at DSE +
recovery. 295 segments developed an ischemic response at peak and another 48 only during
recovery phase.
During DSE 43 patients had ≥4 viable segments. During the recovery phase another 6
patients were considered as viable (Figure). These were patients that changed from non-
viable i.e. unchanged response to dobutamine at peak, to ischemic indicating a prolonged
ischemic effect of dobutamine during the recovery phase, after acute beta-blocker injection.
Only 3 of these patients had a ≥5% increase in left ventricular ejection fraction 12 months after
revascularization.
Figure:  Patients with viability at DSE versus DSE + recovery (p<0.03 after controlling for DISA-SPECT
results).
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DISA-SPECT and Radionuclide ventriculography
Viability was detected in 463 (59%) segments, while 154 (19.7%) segments presented as
scar. The rest of the segments had normal or mildly reduced function and metabolism. Mean left
ventricular ejection fraction as assessed by radionuclide ventriculography was 28% ±7% prior
to revascularization and 37% ± 6% post revascularization.
DSE in viability estimation
Table 2 shows the respective changes of sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) for the detection of viability at DSE and DSE+recovery
and by using DISA-SPECT as reference. The sensitivity at low-high DSE for viability estimation
was 72% (95% CI 68% to 76%) and specificity 74% (95% CI 72% to 76%). When recovery
images were also analyzed the sensitivity for viability estimation increased to 85% (95% CI 81%
to 89%), while specificity remained unchanged.
Patients on chronic beta-blockade did not show any difference in sensitivity compared to the
group that did not receive chronically beta-blockers.
Using k-statistics, the detection of agreement between DISA-SPECT results and DSE re-
sults increased from 0.55 at low-high DSE to 0.68 at DSE + recovery, indicating a good agree-
ment of DSE with the nuclear findings when recovery phase was also scored.
Multivariate regression analysis showed that, DSE+recovery phase results in total were the
only independent predictors of improved left ventricular function (ejection fraction improvement
≥5%) after revascularization (p=0.04, odds ratio [OR] 14.65, 95% CI 1.34 to 133.7). Further-
more the number of scarred segments as shown by DISA-SPECT, was the only independent
Table 2: Sensitivity, specificity, accuracy, positive predictive value and negative predictive value
 for viability evaluation at DSE and DSE+recovery.
DSE DSE+recovery p
Sensitivity 72% 85% 0.001
Specificity 74% 78% ns*
Accuracy 73% 82% 0.01
Positive Predicitve
Value 80% 85% ns*
Negative Predicitive
Value 65% 78% 0.001
ns* = non-significant
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predictor of deterioration of left ventricular function after revascularization, in multivariate analy-
sis (p=0.03, OR 0.78, 95% CI 0.62 to 0.98).
Discussion
Dobutamine stress echocardiography is widely used for viability detection in patients with
CAD [11-14]. However the sensitivity of the test is less than in other imaging techniques, with a
slightly better specificity [11-14]. In this study we demonstrated that the sensitivity increased
from 72% to 85% (p<0.001) when recovery phase was also scored and more importantly it was
not accompanied by a decrease in specificity. Furthermore the negative predictive value of the
test was also significantly improved (Table 2).
Previously, Tsoukas et al.[15] have studied the presence of myocardial ischaemia during
the recovery phase of DSE. Their results have shown that patients with extended coronary
artery disease have more prolonged ischaemia. Furthermore, Mathias et al.[3] have demon-
strated that injection of beta-blockers at the peak dose of DSE might enhance regional wall
abnormalities and increase the sensitivity of the recovery images for detecting ischemia. We
similarly found an enhanced sensitivity in our study. Moreover as no myocardial infarction or
ventricular fibrillation was recorded during or attributed to DSE we could support that the use
of acute beta-blockade during DSE is safe. Concerning viability, a study by Zaglavara et.al.[16]
has suggested that beta blocker withdrawal is not necessary before DSE studies as far as a
completed DSE protocol is performed. This is required as some viability can be detected at
higher doses than the traditional low dose stages. Our protocol also included recovery phase
evaluation as part of standard DSE.
In our study during the recovery phase the status in 6 patients changed from “non-viable” at
peak i.e. unchanged response to dobutamine, to “viable” i.e. ischemic (p=0.03) (Figure), indi-
cating a prolonged ischemic effect of dobutamine during the recovery phase, after acute beta-
blocker injection. This is also indicated by the value of rate-pressure product during the recovery
phase, as a measure of oxygen consumption rate, which was less than its value at peak stress, but
more than the value at rest. Dobutamine stimulates â1, â2, and Æ1-adrenergic receptors[17].
Acute â-blockade interacts with dobutamine â1 and â2 receptors leaving unopposed Æ1-adren-
ergic vasoconstriction [18] and therefore leading to reduction of coronary flow reserve[19]. This
means that increased vasoconstriction can cause myocardial ischemia and that could also explain
the paradoxical enhancement of ischemic response at the recovery phase.
Our findings have also demonstrated that viability estimation by the combination of low, peak,
and recovery phase scoring was the only independent predictor of improved left ventricular
function after revascularization. Indeed this finding was similar to that of a previous study that has
shown that DSE is both sensitive and specific in predicting improved myocardial function after
revascularization [16]. Furthermore Afridi et.al [20] demonstrated that myocardial viability was
the only multivariable predictor of good outcome after revascularization.
We have also found a good correlation between the two imaging techniques for detecting
myocardial viability when recovery phase was also scored, and irrespectively of resting left ven-
tricular ejection fraction; a finding that is in concordance with previous studies. [1,14,16,20-22]
To our knowledge this is the first study demonstrating the additional value of the recovery
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phase of DSE in the estimation of viability in patients with CAD. An increased sensitivity of the
test, as we found, could add to the clinical usage of DSE in this respect.
Possible limitations of our study could include the fact that the study population consisted of
patients with chronic ischemic LV dysfunction. Findings may not apply to patients with acute or
recent myocardial infarction. Another limitation could be the subjectivity of DSE interpretation.
This potential limitation may be reduced by the introduction of automatic quantitative scoring
systems. A third limitation was the large number of scarred nonviable segments. Limitations also
include that the specificity of the reference method could be expected to be low and that there
was not a follow-up echo 12 months after revascularization. Global left ventricular function im-
provement as estimated by radionuclide ventriculography was selected for evaluation post re-
vascularization over the actual recovery on a segmental level as it is an acceptable and important
clinical surrogate which is easily understood by most general physicians.
In conclusion the assessment of myocardial viability by DSE in patients with coronary artery
disease has improved sensitivity when scoring of individual segments at recovery phase becomes
an integral part of the regular DSE scoring.
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Abstract
Objective: To assess the prognostic value of wall motion abnormalities (WMA) during re-
covery phase of dobutamine stress echocardiography (DSE) in addition to WMA at peak stress.
Methods: WMA were assessed at peak and during recovery phase of DSE in 187 consec-
utive patients, who were followed for occurrence of cardiac events.
Results: During follow up (mean 36 months±28), 19 patients (10%) died from cardiac
causes, 34 (18%) patients suffered non-fatal myocardial infarction and 77 (41%) patients under-
went late revascularization. Univariable  predictors of cardiac events by Cox regression analysis
were age (hazard ratio HR1.01 confidence interval CI1.00-1.03), dyslipidaemia (HR1.41 CI1.02-
1.95), rest WMA (HR1.37, CI 1.14-1.64), new WMA (HR1.18 CI 0.95-1.45) at peak and
new WMA (HR1.33, CI 1.11-1.59) at recovery phase of DSE. The best multivariable model to
predict cardiac events included new WMA (HR5.34 CI 1.71-16.59) at recovery phase of DSE,
after controlling for clinical and peak DSE data.
Running head: Significance of ischemia during recovery phase of stress echocardiography
Keywords: Dobutamine Stress Echocardiography, ischemia, risk stratification
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Conclusions: Myocardial ischemia at recovery phase of DSE is an independent predictor of
cardiac events and has an incremental value when added to ischemia at peak.
Introduction:
Dobutamine Stress Echocardiography (DSE) is one of the leading non-invasive imaging tech-
niques for detection of coronary artery disease (CAD), viability estimation and for prognosis and
risk stratification in the setting of CAD and prior to non-cardiac surgery1. Its safety accuracy and
feasibility have well been established2. Several studies have demonstrated the high predictive
value of DSE for long-term cardiac events in a large group of patients3. However the role of the
recovery phase of DSE is underestimated and its value in long term prognosis of patients is yet to
be determined. The aim of our study is to assess the additional prognostic value of reversible wall
motion abnormalities (myocardial ischemia) of the recovery phase of DSE, compared to is-
chemia at peak stress, for long-term cardiac events.
Methods:
Patient population
The study population included 200 consecutive patients who were referred to DSE for the
evaluation of suspected or known CAD at the Thoraxcenter (Rotterdam, the Netherlands) be-
tween March 2001 and March 2003, who were unable to perform an adequate exercise test
and underwent coronary angiography within 3 months of DSE. Thirteen patients underwent early
coronary revascularization, in the first 60 days after DSE, and were excluded from the analysis
as the decision for the revascularization might be influenced by the results of DSE. Therefore the
final analysis included 187 patients. Diabetes mellitus was defined as fasting plasma glucose level
of ≥126 mg/dl on at least two occasions and/or requirement for insulin or oral hypoglycaemic
agents, according to the criteria by the American Diabetes Association4,5. Hypercholesterolemia
was defined as total cholesterol of 200 mg/dl or use of a cholesterol-lowering agent. Hyperten-
sion was defined as systolic blood pressure of 140 mmHg, diastolic blood pressure of 90 mmHg,
or use of antihypertensive medication. Heart failure was defined according to the New York
Heart Association classification. The local medical ethics committee approved the study proto-
col. Patients gave an informed consent to undergo the study.
Dobutamine stress echocardiography
The DSE protocol was approved by the local medical ethics committee and was performed
in accordance with well-established protocols6-8. Studies were performed using a Sonos 5500
imaging system (Phillips Medical Systems, Eindhoven, The Netherlands). Patients underwent a
resting two-dimensional echocardiographic examination from the standard apical and paraster-
nal views. Images were recorded on videotape and also digitized for comparison of different
stages. Dobutamine was then administered intravenously by infusion pump, starting at 5 mg/kg/
min for 3 minutes, followed by 10 mg/kg/min for 5 minutes and increasing by 10 mg/kg/min every
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3 minutes to a maximum of 40 mg/kg/min (stage 5), and continued for 6 minutes. The dob-
utamine infusion was stopped if a target heart rate (85% of a theoretic maximal heart rate (men:
(220 – age) x 85%; women: (200 – age) x 85%) was achieved. If the target heart rate was not
achieved and patients had no symptoms or signs of ischemia, atropine (starting with 0.25 mg,
increased to a maximum of 2.0 mg) was given intravenously at the end of stage 5 while the
dobutamine administration was continued. During the test, a 12-lead ECG was recorded every
minute. Blood pressure was measured at the end of every dobutamine infusion stage. Metoprolol
was administered (1,0 to 5,0 mg) intravenously according to heart rate response and systolic
blood pressure, and after peak stress images were acquired, to achieve a recovery phase, de-
fined as heart rate within 10% range of resting heart rate.
The criteria for stopping the test were: (1) achievement of the target heart rate (2) severe and
extensive NWMA, (3) horizontal or downsloping ST depression of ≥0.2 mV measured 80 ms
after the J point, or ST-segment elevation of ≥0.2 mV in the absence of Q waves, (4) symptom-
atic decline in systolic blood pressure of more than 40 mmHg, or a systolic blood pressure ≤90
mmHg, (5) hypertension (blood pressure >240/140 mmHg), (6) the occurrence of sustained
cardiac arrhythmias, (7) severe angina pectoris, and (8) intolerable adverse effects considered to
be the result of dobutamine or atropine. Two experienced investigators performed off-line as-
sessment of echocardiographic images without knowledge of the patient’s clinical and coronary
angiography data, but with knowledge of the doses of dobutamine and atropine used. Regional
function was scored according to a 16 segment, five point scoring model: 1, normal; 2, mildly
hypokinetic; 3, severely hypokinetic; 4, akinetic; and 5, dyskinetic. The results of DSE were
considered positive if NWMA occurred (i.e., if wall motion in any segment worsened by ≥1
grades during the test, with the exception of akinesis becoming dyskinesis). The extent and
location of ischemia were evaluated and a wall-motion score index (WMSI) (total score divided
by the number of segments scored) was calculated, at rest, during peak stress, and during the
recovery phase. Digital screen format was used to compare images. When there was disagree-
ment between the two assessors, a third investigator viewed the images without knowledge of
the previous assessments, and a majority decision was reached.
Coronary angiography
The presence of CAD was established by standard quantitative coronary angiography using
the Judkins technique. A luminal diameter stenosis > 70% in a major epicardial vessel was con-
sidered significant. Multivessel CAD was defined by the presence of significant stenosis of two
or three vessels, or more than 50% stenosis of the left main stem. The operators were blind to
DSE results.
Long term follow up
Follow-up data were obtained in 2006 for the period between 2001 and 2003. The mean
period of follow-up was 36 ± 28 months after DSE. Physicians who were unaware of patients’
stress test results assessed events. There was a formal centralized adjudication process. The
present status was determined by contacting the patient’s general physician and/or review of the
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hospital records. The date of the last interview or review was used to calculate the follow-up
time. Evaluated end points were cardiac death, myocardial infarction, and late coronary revas-
cularization. Cardiac death was defined by clinical data of acute myocardial infarction and/or
significant cardiac arrhythmias and/or refractory congestive heart failure, together with ECG and
autopsy studies when available. Elevations of cardiac isoenzyme levels and development of new
ECG changes defined a nonfatal myocardial infarction. Revascularization by coronary angio-
plasty or bypass surgery 6 months after the original DSE was considered to reflect new or
progressive symptoms. In patients with more than one cardiac event, the worst event was cho-
sen: documented cardiac death (worst), nonfatal infarction (less worst), and coronary revascu-
larization (least worst).
 Statistical analysis:
Characteristics were summarized as percentages for categorical variables and as mean
standard deviation for continuous variables. Univariate and multivariate analysis of clinical and
echocardiographic variables with the end points were assessed using the Cox proportional
hazards model. All clinical variables and representative DSE variables were considered in the
model, regardless of their univariate significance. Variables were selected in a stepwise for-
ward selection manner with entry and retention set at a significance level of 0.05. The incre-
mental value of the recovery phase of DSE over the clinical variables in the prediction of
events was assessed by adding various echocardiographic data to clinical and stress test pa-
rameters. More specifically, three modelling steps were used: 1) clinical variables alone, 2)
clinical, rest, and stress echocardiographic variables and 3) clinical, rest, and stress and re-
covery echocardiographic variables were compared via their log likelihood ratio chi-square
statistics. The fitted model included age only for the purpose of adjustment; all other models
were based on the variables selected in the stepwise algorithm, which were replaced by di-
chotomous versions to facilitate ease of clinical use. The risk of a variable was expressed as a
hazard ratio (HR) with a corresponding 95% confidence interval (CI). The probability of
cardiac event-free survival was calculated by the Kaplan-Meier method and the resulting
curves were compared by the log rank test9,10. All analyses were performed using SPSS-11.0
statistical software (SPSS Inc., Chicago, Illinois).
Results:
Patient Characteristics and Hemodynamic response
Patients’ clinical characteristics are presented in Table 1. The patients’  medication was al-
tered accordingly to DSE results and clinical symptoms during the study. During DSE the heart
rate increased significantly from rest to peak stress. Test end point was target heart rate and was
reached in 94% of patients. Atropine was added at peak stress in 120 patients as the majority
was on chronic beta-blockade. The mean maximal dobutamine dose was 38 ± 8 mcg/kg/min.
Side effects included hemodynamically stable sustained ventricular tachycardia (>10 complexes)
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in 2 (1%) patients , non-sustained ventricular tachycardia (<10 complexes) in 6 (3%) patients,
atrial fibrillation in 4 (2%) patients and severe hypotension (decrease of systolic blood pressure
>40mmHg) in 2 (1%) patients. No myocardial infarction or ventricular fibrillation was recorded
or attributed to DSE.
Echocardiographic and Angiographic data
Rest wall motion abnormalities were observed in 123 (66%) patients. New WMA were
present in 176 (94%) patients in total, 131 (70%) had new WMA at both peak and recovery
phase, while 45 (24%) patients had new WMA only in the recovery phase after acute beta-
blockade. During peak stress new WMA were present in 58 single-vessel disease and in 73
multi-vessel disease patients while during the recovery phase in 88 single- and 88 multi-vessel
disease patients respectively. Furthermore all patients that showed ischemia at peak stress had
persisting abnormalities after acute beta-blockade. Thirty single-vessel disease patients exhib-
Table 1: Study population characteristics
Demographics
Males 136 (73%)
Females 51 (27%)
Age 59–11
Cardiovascular History and
cardiac risk factors
Hypertension 65 (35%)
Heart Failure 41 (22%)
Diabetes Mellitus 34 (18%)
Previous Myocardial Infarction 99 (53%)
Dyslipidemia 95 (51%)
Smoking 47 (25%)
Previous PCI
103 (55%)
Cardiac Medication at baseline
ACE-inhibitors 84 (45%)
Aspirin 49 (26%)
Statins 41 (22%)
â-blockers 120 (64%)
Nitrates 105 (56%)
Diuretics 41 (22%)
Digoxin 11 (6%)
Characteristics in 187 patients
KARAGIANNIS et al46
ited myocardial ischemia only during the recovery phase. Multivariate regression analysis showed
that, new WMA in the recovery phase were the only independent predictors for single-vessel
disease patients (odds ratio [OR] 6.24, 95% CI 2.61 to 14.9). The rate pressure product
values at rest, peak and recovery were 8694 ± 286, 13910 ± 546 and 10648 ± 299 respec-
tively. WMSI at rest was 1.78 ± 0.69, peak 1.90 ± 0.83 and at recovery 2.10 ± 0.95.
Coronary angiography revealed 88 (47%) single vessel disease patients, 49 (26%) two-ves-
sel disease patients and 39 (21%) three-vessel disease patients. All patients with angiograph-
ically single-vessel disease presented myocardial ischemia during the recovery phase of DSE;
58 during both peak and recovery phase and 30 only in the recovery phase after acute beta-
blocker administration.
Table 2: Predictors of late cardiac events (cardiac death, MI, late
               revascularization)
       Univariable predictors        Multivariable predictors
HR 95% CI p Value HR 95% CI p Value
Diabetes 1.23 0.81 to 1.85 NS 2.23 1.10 to 4.49 0.024
HTN 1.06 0.75 to 1.49 NS
Smoking 1.33 0.91 to 1.93 NS
Dyslipidaemia 1.41 1.02 to 1.95 0.04
Previous MI 1.35 0.98 to 1.87 NS
CHF 1.20 0.82 to 1.75 NS 2,56 1.00 to 6.55 0.05
b-blockers 0.57 0.40 to 0.80 0.02
Age 1.01 1.00 to 1.03 0.02 1.04 1.02 to 1.05 0.005
WMA rest 1.37 1.14 to 1.64 0.001
NWMA peak 1.18 0.95 to 1.45 0.003
NWMA rec 1.33 1.11 to 1.59 0.002 5.34 1.71 to 16.59 0.004
HTN: Hypertension
CHF: Congestive Heart Failure
NWMA rec: New Wall Motion Abnormalities at recovery
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Intra- and interobserver variabilities
We observed good intraobserver agreement for images at rest (r = 0.90), low dose (r =
0.93), peak dose (r = 0.88), and recovery (r = 0.88, all p values <0.001). Moreover, global
interobserver agreement was 88%.
Follow up
Follow up was successful for 187 patients. All cause mortality was 13% (25 patients), of
which 10% (19 patients) was attributed to cardiac causes. Thirty-four (18%) patients suffered
non-fatal myocardial infarction and 77 (41%) patients underwent late revascularization. Overall
130 (69%) patients had at least one cardiac event.
Predictors of late Cardiac Events
Univariate and multivariate predictors of late cardiac events (cardiac death, non-fatal myo-
cardial infarction and late revascularizations) are summarized in table 2.
Univariable independent predictors of late cardiac events included age, dyslipidaemia, WMA
at rest and new WMA at peak and recovery phase of DSE. Among clinical variables age, the
presence of heart failure and diabetes were multivariable independent predictors of late cardiac
events. Moreover myocardial ischemia estimation at recovery was the only DSE parameter,
independently predicting late cardiac events in multivariate analysis. Similarly, although under-
powered due to limited number of hard events, myocardial ischemia during the recovery phase
was independently predicting in a trend line manner all-cause mortality and non-fatal myocardial
infarction. Figure 1 illustrates the incremental contribution of myocardial ischemia at recovery
phase of DSE over clinical data and ischemia at peak DSE, for prediction of late cardiac events.
Kaplan-Meier survival curves for the end point of late cardiac events in patients with myocar-
dial ischemia at both peak and recovery phase of DSE, versus myocardial ischemia only in the
recovery phase of DSE, are presented in figure 2.
Discussion:
In the present study we assess the incremental value of myocardial ischemia at the recovery
phase of DSE for prediction of late cardiac events, in 187 patients with known or suspected
CAD. During a mean follow up of 36 (±28) months, 130 (69%) patients had at least one
cardiac event. Coronary angiography showed that patients with single-vessel disease were
more accurately diagnosed by new WMA during the recovery phase compared to peak stress
[OR 6.24, 95% CI 2.61 to 14.9]. Univariate analysis showed that among others, rest and
DSE parameters were positively related to the risk of developing late cardiac events. Multi-
variable analysis results showed that clinical predictors of late cardiac events were diabetes,
congestive heart failure and age. However the presence of myocardial ischemia (NWMA)
during recovery phase was the only independent DSE predictor of late cardiac events. In fact
this model proved to have the best predictive value for late cardiac events (HR 11.17, x²
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39.140) as shown in figure 1. Patients that exhibited ischemic response only in the recovery
phase and after acute beta-blockade had a delayed event than those that presented ischemia
at peak. The two survival curves crossed each other at 24 months of follow up. A possible
explanation could be the fact that these patients were predominantly single-vessel disease
patients (30 single-vessel disease patients vs 15 multi-vessel disease patients) with milder
extent of ischemia than those with reversible wall motion abnormalities at peak DSE. Mathias
et al11 have demonstrated that injection of beta-blockers at the peak dose of DSE might
enhance regional wall abnormalities and increase the sensitivity of the recovery images espe-
cially in single-vessel disease patients. So recovery phase mainly offers additional predictive
information in patients that have a missed ischemic response at peak DSE.
Dobutamine and recovery phase of DSE
A possible explanation of our DSE results is that at the recovery phase we could better
visualize the ischemic segments that already existed at peak stress but were masked by hyperdy-
namic contraction of mid- and epicardial layers. Dobutamine stimulates â1, â2, and Æ1-adrener-
gic receptors12. Acute â-blockade interacts with dobutamine â1 and â2 receptors leaving unop-
posed Æ1-adrenergic vasoconstriction13 and therefore leading to reduction of coronary flow
reserve14. This means that increased vasoconstriction can cause myocardial ischemia and that
49THE LONG PROGNOSTIC VALUE OF WALL MOTION ABNORMALITIES DURING THE RECOVERY PHASE OF
DOBUTAMINE STRESS ECHOCARDIOGRAPHY AFTER RECEIVING ACUTE BETA-BLOCKADE
could also explain the paradoxical enhancement of wall motion abnormalities at the recovery
phase. Moreover we found that the value of rate-pressure product during the recovery phase, as
a measure of oxygen consumption rate, was less than its value at peak stress, but more than the
value at rest. This indicates a prolonged ischemic effect of dobutamine during the recovery phase.
We also have to mention the potential role that myocardial stunning (with or without the
influence of beta-blockers) may have in producing NWMA in recovery. Wall motion abnormal-
ities in recovery that are not apparent at peak stress may be due to worsening of post-stress
abnormalities with stunning.
 Comparison with previous studies
Several studies have demonstrated that DSE can be used as a prognostic tool for a large pool
of patients3,15,16, alternatively to other stress modalities1,2,17. So far there has been evidence that
myocardial ischemia based on reversible wall motion abnormalities at peak DSE, predict pa-
tients that have increased risk of developing late cardiac events, even if they are asymptomatic
after coronary intervention18. There are also a number of studies demonstrating the predictive
value of myocardial ischemia at peak DSE, in several subgroups of patients18-25. Peak dob-
utamine wall motion score index, which measures the sum of resting and stress-induced wall
motion abnormalities, has been shown to be incremental to clinical data in the prediction of all
causes of mortality15,16. This is related to the “combined” information of DSE, which provides
information on left ventricular function at rest, functional improvement at low-dose dobutamine in
segments with rest dyssynergy, and the presence and extent of myocardial ischemia at peak
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DSE3,15,16,25. Nevertheless, to our knowledge this is the first study assessing the incremental value
of myocardial ischemia in the recovery phase of DSE in a predictive model, for prognosis of late
cardiac events despite the fact that there were only a modest number of hard events (death and
MI).
A possible clinical implication of the present study is that future development of quantitative
automatic wall motion scoring systems could include recovery phase in addition to peak images
scoring.
Study limitations
During follow-up, only 19 patients died due to cardiac causes. That was a small number of
patients to provide valuable prediction model for cardiac mortality. On the other hand that could
be attributed to the substantial progress in the treatment of CAD. As our hospital is a referral
centre, 55% of our study population had undergone a revascularization procedure and 53% had
suffered an MI prior to DSE. That could explain the high prevalence of disease of the study
population and the small number of normal subjects.
Conclusions
In conclusion observation and scoring of individual segments at recovery phase, as part of the
regular DSE scoring, improve the assessment of myocardial ischemia in CAD patients and pro-
vide incremental prognostic value for cardiac events, when compared to peak.
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Abstract
Patients with heart failure (HF) scheduled for vascular surgery have increased risk for adverse
postoperative outcome, stratification usually depends on dichotomous risk factors. We sought to
develop a quantitative prognostic model for HF patients using wall motion patterns during dob-
utamine stress echocardiography (DSE).
We studied 295 consecutive patients (mean age: 67±12 years) with ejection fraction ?35%.
During DSE wall motion patterns of dysfunctional segments were scored as scar, ischemia or
sustained improvement. Cardiac death and myocardial infarction were noted perioperative and
during 5 year follow-up. Of 4572 dysfunctional segments; 1783 (39%) had ischemia, 1280
(28%) sustained improvement and 1509 (33%) scar. In 212 patients ≥1 ischemic segments
were present; 83 had only sustained improvement. Perioperative and late cardiac events were
20% and 30% respectively. Using multivariate analysis the number of ischemic segments were
associated with perioperative cardiac events (odds ratio (OR) per segment 1.6; 95%CI 1.05-1.8),
Running head: Patients with heart failure scheduled for non-cardiac surgery. Total word count: 2782
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while the number of segments with sustained improvement were associated with improved out-
come (OR per segment 0.2; 95%CI 0.04-0.7). Multivariate independent predictors of late car-
diac events were age and ischemia. Sustained improvement was associated with improved sur-
vival. We demonstrated that DSE provides an accurate risk stratification of HF patients under-
going vascular surgery.
Keywords: Heart Failure, Dobutamine Stress Echocardiography, vascular surgery.
Introduction
Preoperative cardiac risk assessment for patients undergoing major vascular surgery is a
challenging entity. Patients are mainly stratified according to the number of dichotomous cardiac
risk factors [1, 2]. At present risk stratification of patients with HF scheduled for vascular sur-
gery mainly depends on resting left ventricular (LV) function, as it is shown that patients with LV
dysfunction have a reduced long-term survival after major vascular surgery [3, 4, 5]. However,
the presence of myocardial viability; i.e. dysfunctional segments that improve after inotropic
stimulation might enhance preoperative risk stratification. A quantification of dobutamine stress
echocardiography (DSE) results would help in this aspect. We tried according to the Bayesian
principle to change the pretest probability in more precise post test quantification of risk and
therefore stratify HF patients more accurately. The aim of our study is to assess the prognostic
implications of ischemia or sustained improvement, as the 2 main patterns of response of viable
tissue to DSE, in patients with known LV ejection fraction < 35%, undergoing major vascular
surgery.
Methods
    The study population included 295 consecutive patients with known LVEF?35%, who
were referred to the Erasmus MC (Rotterdam, the Netherlands) for major vascular non-cardiac
surgery, between June 1999 and June 2001. All patients underwent DSE examination for evalu-
ation of viability. Diabetes mellitus was defined as fasting plasma glucose level of ≥126 mg/dl on
at least two occasions and/ or requirement for insulin or oral hypoglycaemic agents, according to
the criteria by the American Diabetes Association [6]. Hypercholesterolemia was defined as
total cholesterol of 200 mg/dl or use of a cholesterol-lowering agent. Hypertension was defined
as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or use of antihy-
pertensive medication. The local medical ethics committee approved the study protocol. Patients
gave an informed consent for the study.
    The DSE protocol was approved by the Hospital Ethical Committee and was performed
in accordance with well-established protocols [7, 8]. Studies were performed using a Sonos
5500 imaging system (Phillips Medical Systems, Eindhoven, The Netherlands). Patients un-
derwent a resting 2-dimensional echocardiographic examination from the standard apical and
parasternal views. Images were recorded on videotape and also digitized for comparison of
different stages. Dobutamine was administered intravenously by infusion pump, starting at 5
mg/kg/min, followed by 10 mg/kg/min for 5 minutes and increasing by 10 mg/kg/min every 3
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minutes to a maximum of 40 mg/kg/min (stage 5), and continued for 6 minutes. The dob-
utamine infusion was stopped if a target heart rate (85% of a theoretic maximal heart rate
(men: (220 – age) x 85%; women: (200 – age) x 85%) was achieved. If the target heart rate
was not achieved and patients had no symptoms or signs of ischemia, atropine (starting with
0.25 mg, increased to a maximum of 2.0 mg) was given intravenously at the end of stage 5
while the dobutamine administration was continued. During the test, a 12-lead electrocardio-
gram was recorded every minute. Blood pressure was measured every 3 minutes. Metoprolol
was administered (1,0 to 5,0 mg) intravenously according to heart rate response and systolic
blood pressure, and after peak stress images were acquired to achieve a recovery phase,
defined as heart rate within 10% range of resting heart rate. The criteria for stopping the test
were: (1) achievement of the target heart rate (2) severe and extensive NWMA, (3) horizontal
or downsloping ST depression of ≥0.2 mV measured 80 ms after the J point, or ST-segment
elevation of ≥0.2 mV in the absence of Q waves, (4) symptomatic decline in systolic blood
pressure of more than 40 mmHg, or a systolic blood pressure ≤ 90 mmHg, (5) hypertension
(blood pressure >240/140 mmHg), (6) the occurrence of sustained cardiac arrhythmias, (7)
severe angina pectoris, and (8) intolerable adverse effects considered to be the result of dob-
utamine or atropine. Two experienced investigators performed off-line assessment of echocar-
diographic images without knowledge of the patient’s clinical and coronary angiography data,
but with knowledge of the doses of dobutamine and atropine used. Interobserver and intraob-
server agreement for analysis of DSE studies were reported previously (92% and 94%, re-
spectively) [9]. Regional function was scored according to a 16 segment, five point scoring
model: 1, normal; 2, mildly hypokinetic; 3, severely hypokinetic; 4, akinetic; and 5, dyskinetic.
Wall-motion score index (WMSI) (total score divided by the number of segments scored)
was calculated, at rest, low dose and during peak stress. Myocardial viability was assessed in
severely dysfunctional segments; 4 types of wall motion responses were observed: (1) bipha-
sic pattern (ischemia): improvement of wall motion at 5, 10, or 20 mg/kg/min dobutamine with
worsening at higher dosages; (2) worsening only (ischemia); (3) sustained improvement; (4)
no change or scar. Severely dysfunctional segments exhibiting a biphasic, sustained, or wors-
ening response were considered viable, whereas segments with unchanged wall motion were
considered scarred.
    Evaluated end points were all cause mortality, cardiac death and non-fatal myocardial
infarction. Cardiac death was defined by clinical data of acute myocardial infarction and/or sig-
nificant cardiac arrhythmias and/or refractory congestive heart failure, together with electrocar-
diographic and autopsy studies when available. Elevations of cardiac isoenzyme levels and de-
velopment of new electrocardiographic changes defined a non-fatal myocardial infarction. In
patients with more than one cardiac event, the worst event was chosen: documented cardiac
death (worst) and nonfatal infarction (less worst). Perioperative cardiac events were considered
as those events that occurred within 30-days after surgery. Follow-up data were obtained in
2006 .The mean period of long-term follow-up was 60 months (± 24) after DSE. Physicians
who were unaware of patients’ stress test results assessed events. The present status was deter-
mined by contacting the patient’s general physician and/or review of the hospital records. The
date of the last interview or review was used to calculate the follow-up time.
    The t-test was used for continuous variable and chi –square test was used for categorical
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variables. Characteristics were summarized as percentages for categorical variables and as
mean ± standard deviation for continuous variables. Univariate and multivariate analysis of
clinical and echocardiographic variables with the end points were assessed using logistic re-
gression analysis for the 30 day post-surgery period and the Cox proportional hazards model
for long-term follow-up. All clinical variables and representative DSE variables were consid-
ered in the model, regardless of their univariate significance. Variables were selected in a
stepwise forward selection manner with entry and retention set at a significance level of 0.05.
The fitted model included age only for the purpose of adjustment; all other models were based
on the variables selected in the stepwise algorithm, which were replaced by dichotomous
versions to facilitate ease of clinical use. The risk of a variable was expressed as hazard ratio
(HR) or odds ratio (OR) with a 95% confidence interval (CI). The probability of cardiac
death free survival was calculated by the Kaplan-Meier method and the resulting curves were
compared by the log rank test [10].
Results
 The patients’ demographics and clinical characteristics are presented in Table 1. The pa-
tients‘ medication was continued during the study.
During DSE the heart rate increased significantly from rest to peak stress. The rate pressure
product values at rest, low, and peak were 8694 ± 286, 13910 ± 546 and 17028 ± 351
respectively. In 91% of patients target heart rate was reached. Atropine was added at peak
stress in 97 patients as the majority was on chronic beta-blocker therapy. The mean maximal
dobutamine dose was 38 ± 8 mcg/kg/min. Side effects included hemodynamically stable sus-
tained ventricular tachycardia (>10 complexes) in 4 (1%) patients , non-sustained ventricular
tachycardia (<10 complexes) in 14 (5%), atrial fibrillation in 4 (1%), and severe hypotension
(decrease of systolic blood pressure >40 mmHg) in 4 (1%). No myocardial infarction or ventric-
ular fibrillation was recorded during or attributed to DSE. The WMSI at rest was 2.08 ± 0.50,
at low dose 1.39± 0.44, and at peak dose 1.89 ± 0.55. From the 4572 dysfunctional segments,
1783 (39%) exhibited an ischemic response, 1280 (28%) had sustained improvement and in
1509 (33%) the motion patterns was unchanged during DSE and therefore were defined as scar.
As expected all these patients with LV dysfunction of ischemic etiology had several degrees of
scar tissue. 212 patients had one or more ischemic segments, while 83 patients experienced only
a sustained improvement during DSE. In 26 patients with severe ischemia during DSE and symp-
tomatic angina not relieved by medication, cardiac revascularization procedure preceded non-
cardiac surgery.
During the early perioperative period i.e. within 30-days after operation, 6 patients died, 34
patients suffered non-fatal acute myocardial infarction and 54 patients experienced an ischemic
cardiac event (elevated isoenzyme levels). From these 54 patients, 47 (87%) had presented
ischemia during DSE and 7 (13%) presented sustained improvement (p< 0.001). From the 34
patients with acute myocardial infarction the respective numbers were 29 (83%) and 5 (15%)
(p< 0.001). Four (15%) out of 26 patients that underwent coronary revascularization prior to
vascular surgery suffered a non-fatal myocardial infarction.
Univariate significant predictors of perioperative cardiac events were cholesterol  ≥200mg/dl
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(OR 1.71, 95%CI 1.03-2.85, p=0.04) and ischemia during DSE (OR 2.77, 95%CI 1.15-6.64,
p=0.001).
 Multivariate analysis showed that an increased number of segments with sustained improve-
ment during DSE compared to the number of ischemic segments was associated with an im-
proved postoperative outcome. The only multivariable independent predictors of early perioper-
ative cardiac events were previous myocardial infarction (OR 1.5, 95%CI 1.05 -2.3), ischemia
(OR 1.6, 95%CI 1.05 -2.8) and sustained improvement during DSE (OR 0.2, 95%CI  0.04-
0.7) (Figure 1). For perioperative all-cause mortality the only independent predictor in multivari-
ate analysis was age (OR 1.03, 95%CI 1.05-1.1).
 Long term follow up was successful for all patients. All cause mortality was 43% (128 pa-
tients), and 70% (89 patients) of that was attributed to cardiac causes. Thirteen (4%) patients
had non-fatal myocardial infarction. Overall 102 (35%) patients had at least one hard cardiac
event. From the 128 patients that died from all causes, only 21 had sustained improvement
during DSE. Furthermore only 11 patients with sustained improvement during DSE died from
cardiac causes and another 3 had a non-fatal myocardial infarction. From the 26 patients that
Table 1: Study population characteristics (n=295)
Males 234 (79%)
Females 61 (21%)
Age (Years) 67 –12
Hypertension 87 (29%)
Diabetes Mellitus 53 (18%)
Previous Myocardial Infarction 158 (54%)
Cholesterol ≥ 200 mg/dl 77 (26%)
Smoking 114 (39%)
Angina      27 (9%)
Previous Percutaneous Coronary
Intervention 21 (7%)
Previous Coronary Artery Bypass 56 (19%)
Grafting
Cardiac Medications
Angiotensin Converting Enzyme -inhibitors 100 (34%)
Aspirin 23 (8%)
Statins 18 (6%)
â-blockers 99 (34%)
Calcium channel-blockers 79 (27%)
Nitrates 71 (24%)
Diuretics 59 (20%)
Digoxin 28 (9%)
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underwent coronary revascularization prior to vascular surgery, 6 died from all causes and 7 had
late cardiac events, 4 of which were fatal myocardial infarction.
Univariate analysis for all-cause mortality showed that beta-blockers use was associated
with an improved outcome (HR 0.61, 95%CI 0.42-0.89, p=0.006). Sustained improvement
(HR 0.71, 95%CI 0.49-1.01, p=0.09) and ischemia (HR 1.21, 95%CI 0.83-1.76, p=0.30)
during DSE, were not significant univariable predictors. However in a multivariate model of
clinical and echocardiographic parameters the only independent predictors of all-cause mor-
tality were age (HR 1.05, 95%CI 1.02-1.07) and ischemia (HR 1.06, 95%CI 1.02-1.12)
during DSE.
Univariable predictors of cardiac events are summarized in table 2. Angina was not significant
univariate predictor for any events (HR 1.0, 95%CI 0.56-1.68, p=0.55). In the multivariate
model age (HR 1.05, 95%CI 1.02-1.08) and ischemia during DSE (HR 1.9, 95%CI 1.1-4.0),
were independent predictors of cardiac events, whereas sustained improvement (HR 0.5, 95%CI
0.3-0.9) proved to be protective.
    Kaplan-Meier curves for the end point of cardiac events in patients with sustained im-
provement versus ischemia during DSE are illustrated in figure2.
Discussion
This study demonstrates the independent prognostic value of wall motion patterns during
DSE in patients with LV dysfunction undergoing major vascular surgery, for the prediction of
cardiac events within 30 days after surgery, and for all-cause mortality and hard cardiac events
Figure 1: Diagram showing the independent multivariate predictors for cardiac events within 30 days
following major vascular surgery in patients with LV ejection fraction < 35%.
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during a long-term mean follow-up of five years.
 Our results showed that sustained improvement during DSE provided a protective effect in
both early perioperative period and long-term cardiac events. On the contrary ischemia proved
to be hazardous in both early and long-term follow up periods. When patients with sustained
improvement were compared to patients with ischemia during DSE they had significantly less
events in the early perioperative period (p< 0.001). Moreover the difference in survival during
long-term follow-up regarding cardiac events between the two different viability responses dur-
ing DSE was also significant (p=0.02) (Figure 2).
Ischemia during DSE also predicted decreased survival in all-cause mortality.
Furthermore the beneficial effect that beta-blockers exert in patients’ survival [11] was recon-
firmed in our study for both all-cause mortality and late cardiac events.
    It is extensively reported that cardiovascular complications are the leading cause of death
after non-cardiac surgery [12, 13, 14]. That was also the case in our study. We found that 70%
of total mortality was attributed to cardiac causes. Furhtermore patients with resting LV dysfunc-
Table 2: Uniavariate predictors of cardiac events (cardiac death and myocardial infarction) in
heart failure patients undergoing major vascular surgery
Univariable predictors Hazard Ratio 95% Confidence Interval          p Value
Previous myocardial
infarction 1.51 1.00 to 2.31 0.05
Hypertension 1.15 0.75 to 1.78 0.51
Smoking 1.05 0.70 to 1.57 0.84
Age 1.00 0.59 to 1.71 0.99
Diabetes mellitus 1.00 0.60 to 1.70 0.99
Beta-blockers 0.62 0.38 to 0.95 0.04
Statins 0.62 0.35 to 1.09 0.07
Ischemia during
low-high dobutamine
stress echocardiography 1.65 0.93 to 2.92 0.06
Sustained improvement
during low-high dobutamine
stress echocardiography 0.72 0.43 to 1.22 0.25
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tion have greatly reduced long-term survival following non-cardiac surgery [14, 15, 16, 17, 18].
Regarding early perioperative outcome this has not been clearly shown maybe due to the inability
of resting LV ejection fracrion to provide information regarding severe underlying coronary ar-
tery disease [14]. Therefore by utilizing DSE we further stratified those patients with resting LV
dysfunction, according to their viability profile. Viable patients with sustained improvement suf-
fered much less cardiac events during the first 30 days following surgery compared to patients
with an ischemic response in low-high DSE. This is in accordance with a previous study by
Landesberg et.al [19]. Although these authors used thallium scan and not DSE, they similarly
found that ischemia was associated with an increased incidence of troponin elevation during the
early perioperative period [19, 20]. Also in a previous study from our group it was shown that
the presence of new wall motion abnormalities during DSE was a powerful determinant of an
increased risk for perioperative events [14, 21]. Other studies also have demonstrated similar
results [22, 23, 24]. However the present study is the only study to our knowledge demonstrat-
ing a clear benefit for patients with LV dysfunction and with sustained improvement during DSE,
regarding the early perioperative outcome. Especially, patients with predominantly sustained im-
provement are at lower risk and might respond favorable to low-dose inotropic stimulation dur-
ing surgery. On the other hand, in patients with predominantly an ischemic response, beta-block-
ers or revascularization could be considered. Previous studies have evaluated the role of extend-
ed ischemia detection in stress echocardiography either with dobutamine [11, 14, 25] or dipy-
ridamole [26] and its correlation with late cardiac events in patients undergoing non-cardiac
Figure 2: Kaplan-Meier curve showing survival from cardiac events in patients with LV ejection fraction
< 35%, undergoing major vascular surgery, with sustained improvement vs ischemia during low-high
DSE.
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surgery. Furthermore it has been shown that the extent of fixed and reversible perfusion defects
on dipyridamole thallium scintigraphy is a significant indicator of late cardiac risk [23, 27]. We
also found similar results regarding the probability of all-cause mortality and long-term cardiac
events. However our study population was more homogeneous as it consisted only of patients
with known LV dysfunction of ischemic origin. Moreover we tried to investigate a further possi-
ble stratification of these patients according to their viability response during DSE. By extensive
internet search of medical libraries we came to the conclusion that our study is the first to our
knowledge demonstrating a beneficial effect of a sustained improvement response during DSE
for viability estimation in this group of patients for the end point of long-term cardiac death.
    A possible limitation of our study is that as an observational one, it relied mainly upon
medical records and administrative data meaning that the effects of some cardiac risk factors
could be biased. Nevertheless most of the predictive values that we found are in concordance
with previous studies both from our and other institutions. Another possible limitation could be
the fact that we did not investigate the impact of response to dobutamine according to the type of
surgery. However the aim of our study was to provide a more accurate stratification of risk of
patients with LV dysfunction irrespective of the type of scheduled surgery.
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Abstract
Background: Dobutamine stress echocardiography (DSE) is used for risk stratification of
patients with suspected coronary artery disease (CAD). However the prognostic value of DSE
among the entire strata of renal function has yet to be determined. We assessed the prognostic
value of renal function relative to DSE findings.
Methods: We studied 2292 patients, divided in 1015 (44%) patients with normal renal
function (creatinine clearance (CrCL)>80ml/min) and 1277 (66%) with renal dysfunction, clas-
sified as mild (CrCl:60-80ml/min) in 647, moderate (CrCl:40-60ml/min) in 403 and severe
(CrCl<40ml/min) in 227 patients. All underwent DSE for evaluation of known or suspected
CAD and were followed for a mean of 8 years.
Results: New wall motion abnormalities during DSE and mildly, moderately and severely
abnormal CrCl were powerful independent predictors for all cause mortality, cardiac death and
hard cardiac events (cardiac death and non-fatal myocardial infarction). Kaplan-Meier curves
demonstrated that patients with normal DSE and renal dysfunction have greater probability for
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cardiac death and hard cardiac events compared to those with normal renal function. The war-
ranty of a normal DSE in the presence of mild, moderate and severe renal dysfunction was 48,
36 and 6 months respectively.
Conclusions: The presence and severity of renal dysfunction has additional independent
prognostic value over DSE findings. The low risk warrantee period after a normal DSE is deter-
mined by the severity of renal dysfunction.
Keywords: Dobutamine Stress Echocardiography, prognosis, renal function.
Running title: DSE and renal function
Introduction
Cardiovascular disease is the major cause of death in patients with renal dysfunction [1]. In
particular, coronary artery disease (CAD) is an important predictor of mortality in chronic renal
failure patients [2]. Dobutamine stress echocardiography (DSE) is a widely used non-invasive
imaging technique for detection of CAD [3]. Several studies have demonstrated the high predic-
tive value of DSE for long-term cardiac events in patients with normal renal function [4]. It has
also been suggested as a tool for risk stratification of patients with chronic renal failure, specifi-
cally in patients undergoing evaluation for kidney transplantation [5]. However the value of wall
motion abnormalities (WMA) during DSE among the entire strata of renal function has yet to be
determined.  The identification of clinical variables that influence prognosis in addition to abnor-
malities on DSE is important to optimize risk stratification in a given patient. The aim of this study
was to assess the prognostic value of renal function relative to DSE findings in patients with
known or suspected CAD.
Subjects and Methods
Study population and baseline measurements
The study population included 2292 consecutive patients with known or suspected CAD
who were referred at the Erasmus MC (Rotterdam, the Netherlands) for DSE between 1993
and 2003. Diabetes mellitus was defined as fasting plasma glucose level of ≥126 mg/dl on at
least two occasions and/or requirement for insulin or oral hypoglycaemic agents, according to
the criteria by the American Diabetes Association [6]. Hypercholesterolemia was defined as
total cholesterol of 200 mg/dl or use of a cholesterol-lowering agent. Hypertension was defined
as systolic blood pressure of 140 mmHg, diastolic blood pressure of 90 mmHg, or use of antihy-
pertensive medication. Heart failure was defined according to the New York Heart Association
classification.
Renal function assessment
Serum creatinine was assessed by a nonkinetic alkaline picrate (Jaffe) method. Creatinine
clearance (CrCl) was computed with the Cockcroft-Gault [7] equation: CrCl (ml/min) = (140-
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age) X weight (kg) ÷ 72 X serum creatinine (mg/dl) (X 0.85 for women) and standardized for
body surface area using the Dubois formula. This equation has close correlation with measured
creatinine clearance and gives a more accurate assessment of renal function than serum creati-
nine alone.
By this definition patients were divided in 4 groups; normal renal function (CrCl > 80ml/min)
and mild (CrCl = 60-80ml/min), moderate (CrCl = 40-60ml/min) and severe (CrCl < 40ml/min)
renal dysfunction. The local medical ethics committee approved the study protocol. Patients
gave an informed consent to undergo the study.
Dobutamine stress echocardiography
The DSE protocol was approved by the local medical ethics committee and was per-
formed in accordance with well-established protocols [8]. Studies were performed using a
Sonos 5500 imaging system (Phillips Medical Systems, Eindhoven, The Netherlands). Pa-
tients underwent a resting two-dimensional echocardiographic examination from the standard
apical and parasternal views. Images were recorded on videotape and also digitized for compar-
ison of different stages. Dobutamine was then administered intravenously by infusion pump,
starting at 5 mg/kg/min, followed by 10 mg/kg/min for 5 minutes and increasing by 10 mg/kg/
min every 3 minutes to a maximum of 40 mg/kg/min (stage 5), and continued for 6 minutes.
The dobutamine infusion was stopped if a target heart rate (85% of a theoretic maximal heart
rate (men: (220 – age) x 85%; women: (200 – age) x 85%) was achieved. If the target heart
rate was not achieved and patients had no symptoms or signs of ischemia, atropine (starting
with 0.25 mg, increased to a maximum of 2.0 mg) was given intravenously at the end of stage
5 while the dobutamine administration was continued. During the test, a 12-lead ECG was
recorded every minute. Blood pressure was measured at the end of every dobutamine infusion
stage.
The criteria for stopping the test were: (1) achievement of the target heart rate (2) severe and
extensive new WMA, (3) horizontal or downsloping ST depression of ≥0.2 mV measured 80
ms after the J point, or ST-segment elevation of ≥0.2 mV in the absence of Q waves, (4) symp-
tomatic decline in systolic blood pressure of more than 40 mmHg, or a systolic blood pressure £
90 mmHg, (5) hypertension (blood pressure >240/140 mmHg), (6) the occurrence of sustained
cardiac arrhythmias, (7) severe angina pectoris, and (8) intolerable adverse effects considered to
be the result of dobutamine or atropine. Two experienced investigators performed off-line as-
sessment of echocardiographic images without knowledge of the patient’s clinical and coronary
angiography data, but with knowledge of the doses of dobutamine and atropine used. Interob-
server and intraobserver agreement for analysis of DSE studies were reported previously (92%
and 94%, respectively) [9]. Regional function was scored according to a 16 segment, five point
scoring model: 1, normal; 2, mildly hypokinetic; 3, severely hypokinetic; 4, akinetic; and 5,
dyskinetic. Wall-motion score index (WMSI) (total score divided by the number of segments
scored) was calculated, at rest, low dose and during peak stress. Digital screen format was used
to compare images. When there was disagreement between the two assessors, a third investiga-
tor viewed the images without knowledge of the previous assessments, and a majority decision
was reached.
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Follow-up
During follow-up, the end-points of the study were all-cause mortality, cardiac death and
hard cardiac events [cardiac death or non-fatal myocardial infarction (MI)]. Clinical information
was obtained by outpatient visits, by mailed questionnaires, by telephone interviews or by re-
viewing hospital records and the electronic patient database. Survival status was obtained by
approaching the referring physician or the municipal civil registries. Cardiac death was defined as
death caused by acute myocardial infarction, cardiac arrhythmias, or congestive heart failure.
Sudden unexpected death was included as cardiac death.
Statistics
The t-test was used for continuous variable and chi –square test was used for categorical
variables. Characteristics were summarized as percentages for categorical variables and as mean
± standard deviation for continuous variables. Univariate and multivariate analysis of clinical and
echocardiographic variables with the end points were assessed using the Cox proportional haz-
ards model. All clinical variables and representative DSE variables were considered in the mod-
el, regardless of their univariate significance. Variables were selected in a stepwise forward se-
lection manner with entry and retention set at a significance level of 0.05. The fitted model includ-
ed age only for the purpose of adjustment; all other models were based on the variables selected
in the stepwise algorithm, which were replaced by dichotomous versions to facilitate ease of
clinical use. The risk of a variable was expressed as a hazard ratio (HR) with a corresponding
95% confidence interval (CI). The probability of all-cause mortality, cardiac death and hard
cardiac events free survival was calculated by the Kaplan-Meier method and the resulting curves
were compared by the log rank test [10, 11].
Results
The patients’ demographics and clinical characteristics are presented in Table 1.
According to renal function the total study population was divided in 1015 (44%) patients
with normal renal function and 1277 (66%) with renal dysfunction. This was classified as mild in
647 patients, moderate in 403 patients and severe in 227 patients. The overall prevalence of
hypertension was 36%.  The respective percentages for mild, moderate and severe renal dys-
function were 34%, 44% and 53%. The prevalence of diabetes in these groups was 13%, 15%,
and 21% respectively.
Patient Characteristics and Hemodynamic response
During DSE the heart rate increased significantly from rest to peak stress. The target heart
rate was reached in 91% of patients. Atropine was administered in 206 patients. The mean
maximal dobutamine dose was 38 ± 8 mcg/kg/min. Side effects included hemodynamically sta-
ble sustained ventricular tachycardia (>10 complexes) in 23 (1%) patients , non-sustained ven-
tricular tachycardia (<10 complexes) in 115 (5%), atrial fibrillation in 23 (1%), and severe hy-
potension (decrease of systolic blood pressure >40 mmHg) in  23 (1%).
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The WMSI was 1.47 ± 0.60 at rest and 1.55 ± 0.67 at peak stress. Rest WMA were
observed in 1469 (64%) patients and new WMA at peak stress were present in 1546 (68%)
patients (Table 2).
Long term follow up
During a mean long-term follow up of 8 years, 543 patients (24%) died, which included 128
(13%) patients with normal CrCl, 145 (22%) with mild renal dysfunction, 156 (39%) with moder-
ate and 114 (50%) with severe renal dysfunction. Cardiac death occurred in 324 patients (14%);
Demographics
Males 1504 (66%)
Females 788 (34%)
Age 61 – 8
Body Mass Index 25.6 – 2.5
Body Surface Area 1.88 – 0.5
Renal Function
Normal 1015 (44%)
Mild dysfunction 647 (28%)
Moderate dysfunction 403 (18%)
Severe dysfunction 227 (10%)
Cardiac risk factors and  history
Hypertension 809 (36%)
Congestive Heart Failure 343 (15%)
Diabetes Mellitus 315 (14%)
High Cholesterol 727 (33%)
Smoking 666 (30%)
Angina 589 (26%)
Previous Myocardial Infarction 805 (35%)
Previous revascularization     PCI 356 (16%)
                                           CABG  346 (15%)
Cardiac Medication
ACE-inhibitors 131 (6%)
Angiotensin receptor blockers 666 (30%)
â-blockers 809 (36%)
Nitrates 315 (14%)
Diuretics 143 (6%)
Digoxin 727 (33%)
Table 1: Study population characteristics (2292 patients).
KARAGIANNIS et al72
the respective numbers among the strata of CrCl was 65 for normal CrCl (6% of normal), 91 for
mild renal dysfunction (14% of mild), 102  for moderate (25% of moderate) and 66  for severe
renal dysfunction patients (29% of severe). Ninety-two (4%) patients suffered non-fatal MI.
Overall 416 (18%) patients had at least one hard cardiac event.
Predictors of all-cause mortality, cardiac death and hard cardiac events
Table 3 summarizes the hazard ratios after multivariate analysis for predictors of all-cause
mortality, cardiac death and hard cardiac events either unadjusted or adjusted for age, sex, prior
MI, prior CABG, prior PCI, congestive heart failure, typical angina, diabetes, hypertension, high
cholesterol and smoking. Ischemia during DSE and mildly, moderately and severely abnormal
CrCl were powerful independent predictors for all end points.
The incremental values (all p< 0.001) per 20 ml/min decrease of CrCl over new WMA during
DSE for the end points of all-cause mortality, cardiac death and hard cardiac events and the
respective improvements in global x2 are shown in figure 1.
Kaplan-Meier curves for the end point of all-cause mortality in patients with normal DSE,
new WMA, ≤ 4 abnormal segments and > 4 abnormal segments during DSE among the entire
strata of renal function are shown in figure 2 (all p<0.001).
Figure 3 demonstrates the Kaplan-Meier curves for cardiac death and hard cardiac events in
patients with normal DSE among the entire strata of renal function (all p<0.01). Patients with
normal DSE and renal dysfunction have greater probability for both cardiac death and hard
cardiac events compared to those with normal renal function.
Kaplan-Meier curves for cardiac death and hard cardiac events in patients with new WMA
and > 4 abnormal segments during DSE among the entire strata of renal function are demonstrat-
ed in figure 4 (all p<0.001).
Table 2: Dobutamine Stress Echocardiography results according to renal function.
Rest WMA*
NWMA×
WMSI+ at rest
WMSI+ at peak
Normal renal
function
(1015 patients)
610 (60%)
640 (63%)
1.47 – 0.61
1.40 – 0.54
Mild renal
dysfunction
(647 patients)
400 (62%)
429 (66%)
1.55 – 0.67
1.47 – 0.60
Moderate renal
dysfunction
(403 patients)
300 (74%)
314 (78%)
1.72 – 0.71
1.63 – 0.65
Severe renal
dysfunction
(227 patients)
159 (70%)
163 (72%)
1.63 – 0.67
1.55 – 0.61
*WMA: Wall Motion Abnormalities
×NWMA: New Wall Motion Abnormalities
+WMSI: Wall Motion Score Index
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Table 3: Multivariate analysis for the end-points of all cause mortality, cardiac death and hard
  cardiac events (cardiac death or nonfatal MI). Hazard Ratios (HR) associated with
  levels  of the creatinine clearance (CrCl) in 2292 patients.
                                    HRs, 95%CIs         HRs, 95%CIs
                                                unadjusted                                adjusted
All cause mortality
NWMA during DSE            1.8 (1.5-2.1)                              1.5 (1.2-1.8)
Normal CrCl                              1.0                                            1.0
Mildly abnormal CrCl             2.0 (1.5-2.5)                             1.4 (1.1-1.9)
Moderately abnormal CrCl         3.9 (3.0-4.9)                              2.3 (1.8-3.1)
Severely abnormal CrCl             5.5 (4.2-7.1)                              3.5 (2.7-4.7)
Cardiac death
NWMA during DSE             2.7 (2.1-3.6)                             1.8 (1.3-2.4)
Normal CrCl                              1.0                                            1.0
Mildly abnormal CrCl             2.4 (1.7-3.3)                             1.7 (1.2-2.4)
Moderately abnormal CrCl        5.0 (3.7-6.9)                               2.8 (2.0-4.1)
Severely abnormal CrCl            6.1 (4.3-8.7)                               3.8 (2.1-4.6)
Cardiac death or MI
NWMA during DSE                    2.3 (1.8-3.0)                             1.6 (1.2-2.0)
Normal CrCl                              1.0                                            1.0
Mildly abnormal CrCl             2.0 (1.5-2.6)                             1.5 (1.1-2.1)
Moderately abnormal CrCl          3.6 (2.7-4.7)                              2.3 (1.6-3.1)
Severely abnormal CrCl             4.8 (3.5-6.5)                             3.3 (2.4-4.7)
Adjusted for age, sex, prior MI, prior CABG, prior PCI, CHF, typical angina, diabetes,
hypertension, high cholesterol, smoking.
Discussion
This study showed the predictive value of renal function relative to DSE findings during a
long-term mean follow up of 8 years. Ischemia during DSE was an independent predictor of
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Figure 1: Incremental value of a 20ml/min decrease of CrCl over NWMA during DSE for the end points
of all-cause mortality, cardiac death and hard cardiac events (cardiac death + MI).
Figure 2: Kaplan-Meier curves for all-cause mortality in patients with (A) normal DSE, (B) NWMA, (C)
≤ 4 abnormal segments and (D) > 4 abnormal segments in DSE and according to renal function, for a
period of 8 years.
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mortality and hard cardiac events among the entire strata of renal function (table 2). The global x2
increased significantly when CrCl, was added to the model (figure1). The degree of renal dys-
function was an additional determinant of survival and hard events among patients with normal as
well as those with abnormal DSE (figures 2, 3, 4). Based on survival curves, we suggest that
patients with severe renal dysfunction should repeat DSE every 6 months even in the absence of
new WMA during the baseline DSE. In patients with mild or moderate renal dysfunction and
normal DSE at baseline we recommend that it should be repeated every 36 and 48 months
respectively (figure 3).
Comparison to previous studies
The American Society of Transplantation has reported guidelines for the pre-transplant eval-
uation of patients with severe renal dysfunction [12]. They included the use of non-invasive
cardiac stress testing, however, it remained unclear which test to use due to the lack of firm
support for a single test. Some studies have suggested that DSE is superior to exercise ECG for
diagnosis of CAD in patients with renal dysfunction [13] and has also prognostic value in this
setting [14, 15, 16]. We also demonstrated the prognostic value of DSE among the entire strata
of renal function. In addition, patients with significant renal dysfunction are often unable to per-
form treadmill exercise testing. Furthermore the presence of left ventricular hypertrophy makes
Figure 3: Kaplan-Meier curves for cardiac death (A) and hard cardiac events (B) in patients with normal
DSE and according to renal function, for a period of 8 years. Patients with normal DSE and renal
dysfunction have greater probability for both cardiac death and hard cardiac events compared to those
with normal renal function. The warranty of a normal DSE in the presence of mild, moderate and severe
renal dysfunction was respectively 48, 36 and 6 months.
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any ST-segment interpretation on ECG less reliable [13]. The theoretical advantages of DSE in
renal dysfunction include maintained sensitivity and specificity in hypertension [17] and bundle
branch block [18].
It is known that early renal failure is associated with changes in traditional and non-traditional
cardiovascular risk factors [1, 2]. Moreover patients with renal dysfunction may have only atyp-
ical or no symptoms of CAD, due to limited activity levels [2]. Avoidance of coronary angiogra-
phy and potentially nephrotoxic contrast material is also critical in these patients. Therefore given
its safety and low cost, DSE could be used as a screening tool in detecting occult CAD before
development of myocardial infarction or sudden cardiac death in patients with renal dysfunction
[19].
A previous study has shown that the accuracy for detecting CAD and the prognostic implica-
tions of positive results of DSE in patients with renal dysfunction appear similar to the general
population [19]. We similarly found that new WMA during DSE were independent predictors
for decreased survival but the addition of CrCl added significantly to the power of the predictive
model (table 2, figure 1).
Although the prognosis of patients with renal dysfunction and normal DSE was better than for
patients with new WMA, the event rate remained substantial for all end points. This could be
explained by the high risk profile of our population and by the known high prevalence of cardiac
Figure 4: Kaplan-Meier curves for cardiac death (A and B) and hard cardiac events (C and D) in
patients with NWMA and > 4 abnormal segments in DSE and according to renal function, for a period
of 8 years.
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events in patients with renal failure even in the absence of coronary artery disease at baseline
because uremia itself provides an atherogenic milieu [16].
In two of the largest prognostic series, the prognostic value of a normal DSE in renal dysfunc-
tion appears to be limited to about 2 years [4, 20]. We have shown in an even larger study
population with a longer follow-up period that the predictive value of a normal DSE in the pres-
ence of mild, moderate and severe renal dysfunction is limited to 48, 24, and 6 months, respec-
tively.
In conclusion we found that renal dysfunction has additional independent prognostic value
over DSE findings, irrespective of the presence and severity of wall motion abnormalities. The
low risk period after a normal DSE is determined by the presence and the severity of renal
dysfunction.
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In this thesis we have demonstrated the role of dobutamine stress
echocardiography in the clinical practice.
In the first part of the thesis we discuss the limitations and advan-
tages of the current methodology of dobutamine stress echocardio-
graphy evaluation. We show that a new, objective technique for the
evaluation of wall motion abnormalities is feasible (chapter 1). This
technique, called automated coupled contour and robust myocardial
tracking, is evaluated in a multicenter study. This seems promising for
the improvement of the sensitivity of dobutamine stress echocardio-
graphy without losing its specificity. In addition, the use of this tech-
nique can resolve one of the major drawbacks of dobutamine stress
echocardiography, the subjective wall motion evaluation. This is a
major cause for a high inter- and intraobserver variability.
Furthermore, we show that a change in the time of wall motion
evaluation during dobutamine stress echocardiography is a simple
and reliable way to improve the sensitivity of the test without losing
its specificity. The evaluation of wall motion abnormalities in the
recovery phase of dobutamine stress echocardiography, after intra-
venous beta-blockade at peak stress, has the potential to improve the
diagnostic accuracy of the test. We demonstrate that this modest
change of the traditional protocol did not lengthen the duration of
the test and importantly, improved the sensitivity for the detection
of coronary artery disease (chapter 2) and myocardial viability (chap-
ter 3).
In the second part of the thesis we show that wall motion abnor-
malities assessed during the recovery phase of dobutamine stress
echocardiography have important long term prognostic value (chap-
ter 4). Patients with heart failure symptoms represent a high risk
population, especially if noncardiac surgery is indicated. In order to
stratify these patients we have developed a prediction model based
on wall motion abnormalities during incremental dobutamine infu-
sion. With the use of this model we were able to stratify patients
with heart failure prior to vascular surgery. Wall motion abnormali-
ties indicative for myocardial viability, ischemia or a biphasic re-
sponse were associated with adverse outcome. However, patients
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that primarily demonstrated a sustained improvement had a favor-
able outcome (chapter 5). In the last chapter we show the diagnostic
accuracy of dobutamine stress echocardiography in a large patient
population with renal dysfunction.
In conclusion, in this thesis we show that wall motion abnormali-
ties assessment during the recovery phase of dobutamine stress
echocardiography is associated with an improved accuracy for the
detection of coronary artery disease in everyday clinical practice.
Dit proefschrift beschrijft de rol van dobutamine stress echocardio-
grafie voor de beantwoording van vragen uit de dagelijkse klinische prak-
tijk. In het eerste deel van dit proefschrift beschrijven we de beperkin-
gen en voordelen van de huidige stress echocardiografie beoordeling.
Tevens demonstreren wij een nieuwe analyse techniek (hoofdstuk 1).
Deze techniek genaamd “automated coupled contour and robust myo-
cardial tracking” werd geëvalueerd bij patiënten in meerdere centra. De
eerste resultaten lijken belovend, de sensitiviteit voor het aantonen van
coronair afwijkingen is toegenomen, zonder vermindering van de spec-
ificiteit van de test. Deze techniek probeert ook één van de onverm-
ijdelijke beperkingen van stress echocardiografie, een hoge interob-
server variabiliteit, op te lossen. Hiervoor wordt gebruik gemaakt van
een objectieve evaluatie van wandbewegingsstoornissen.
We laten zien dat de evaluatie van wandbewegingsstoornissen tijdens
de herstelfase van dobutamine stress echocardiografie, na intraveneuze
bètablokkade tijdens maximale stress, een eenvoudige en betrouw-
bare manier is om de sensitiviteit van de huidige test te verbeteren
zonder de specificiteit te verminderen. We tonen aan dat deze sim-
pele verandering van het traditionele protocol de duur van de test niet
verlengd. De sensitiviteit voor de detectie van coronair vaatlijden
(hoofdstuk 2) en voor inschatting van vitaliteit (hoofdstuk 3) werd
tevens sterk verbeterd.
In het tweede deel van dit proefschrift demonstreren wij de waarde
van wandbewegingsstoornissen tijdens de herstelfase van de dob-
utamine stress echocardiografie als onderdeel van de beoordeling voor
het voorspellen van lange termijn uitkomst (hoofdstuk 4). In een se-
lecte groep van patiënten die een vaatoperatie moesten ondergaan,
ontwikkelden wij een predictie model voor het voorspellen van post-
operatieve complicaties. In dit model gebruiken wij verschillende
patronen van wandbewegingen tijdens toenemende dobutamine dos-
ering. De aanwezigheid van wandbewegingsstoornissen die myocard
vitaliteit aantonen identificeert hoog risico patiënten. Dit leidt tot
een betere risicostratificatie (hoofdstuk 5). In het laatste hoofdstuk
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van dit proefschrift hebben wij de voorspellende waarde van dobutamine
stress echocardiografie onderzocht voor het aantonen van coronair
lijden bij patiënten met een gestoorde nierfunctie, geschat door mid-
del van kreatinine klaring.
Concluderend, in dit proefschrift hebben wij met eenvoudige meth-
oden de klinische toepassing van dobutamine stress echocardiografie
verbeterd voor de hedendaagse klinische praktijk.
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